| In Alzheimer's disease (AD), cholinergic dysfunction (often with reduced acetylcholine tone and impaired choline metabolism) is linked with cortical dysfunction, memory deficit, abnormal cerebral blood flow, task learning difficulty, sleep-cycle disruption, and neurodevelopmental effects (context-dependent). CORE HALLMARKS / HIGH-CONFIDENCE AXES: - tau and Aβ, their accumulation in AD brains is known to be a major hallmark. In AD, PP2A↓ activity is decreased (reported), contributing to hyperphosphorylated tau accumulation. SIRT-1↓ levels in AD brains are associated with accumulation of Aβ and tau (reported). - glucose metabolism↓ (brain glucose hypometabolism) occurs in AD long before significant clinical signs in many cohorts/models (reported). - Neuroinflammation / lipid mediator tone (reported): 5-LOX↑ and PGE2↑ (model-/region-dependent). - Synaptic vulnerability (reported): PSD95↓ in hippocampus and cortex; restoring PSD95 shows cognitive benefits in models. - Clearance/transport imbalance (reported): IDE↓, NEP↓, LRP1↓, and AEP↑ protein levels in AD brains (reported). COMMONLY REPORTED DIRECTIONAL CHANGES (model/region/compartment dependent): - Monoamines (reported): concentrations of 5-HTP↓, 5-HT(seratonin)↓, and 5-HIAA↓ are lower in Alzheimer's patients (varies by region/study). - Cholinergic system (clinical target): reduction in ACh↓ production; ChAT↓ activity reduced (synthesizes ACh). - Four key enzymes frequently targeted in AD symptom/adjunct strategies: AChE, BChE, MAOA, MAOB (objective inhibit). - Neurotrophic tone (reported): BDNF↓ in key regions. - Stress can decrease expression of brain-derived neurotrophic factor (BDNF). - Kinase/protease stress (reported): CDK5↑ hyperactivation; calpain↑ overactivated by increased intracellular Ca²⁺ → p-tau and aggregation. - Aβ-linked synaptic regulator (reported): STEP↑ upregulated largely due to Aβ oligomer accumulation. - α-secretase axis (reported): ADAM10↓ downregulated in AD brains. - Metabolic cofactors (reported): ALC↓ (ALCAR); Homocarnosine↓ (CSF declines with age); possible low Taurine↓ (age-related + dementia reports). - Ion/glutamate handling (reported): impaired glutamate clearance + depressed Na+/K+ ATPase → cellular ion imbalance risk. - Aging reduces NAD⁺↓ (in AD depletion may be more severe). - Mitochondrial capacity axis (reported): PGC-1↓ decreased in Alzheimer’s brains. - Innate immune DNA-sensing axis (animal): cGAS–STING↑ elevation observed in AD mice and normalized by NR treatment. - Vascular/structure (reported): a profound change in BBB permeability; progressive brain shrinkage (atrophy). - Glycation axis (reported): AGEs↑ and RAGE↑ expression. HOMOCYSTEINE / B-VITAMIN AXIS: - Raised plasma total homocysteine (tHcy)↑ associated with cognitive impairment, AD, or vascular dementia (epidemiology). - Homocysteine can build up if vitamin B6, B12, or folate levels are low. - Homocysteine and B-vitamin in Cognitive Impairment (VITACOG) study. - Vit B6 might be an important B vitamin (often discussed along with B12 and folate). - Thiamine↓ deficiency produces a cholinergic deficit (well-aligned with AD features). - Decreased thiamine (B1) in AD may exacerbate Aβ deposition, tau hyperphosphorylation, and oxidative stress (reported). MICRONUTRIENTS / CAROTENOIDS (reported; compartment-dependent): - vitamin A↓ and β-carotene↓ lower in some AD cohorts; excess retinol may contribute to osteoporosis risk. - Diminished circulating vitamin E↓ reported in AD. - Vitamin B5↓ in multiple brain regions (reported). - Trace elements: patients with AD reported lower serum Se, Cu, and Zn↓ (serum findings vary by study). - Brain metals: some studies report higher brain copper↑ and iron↑ in specific regions/structures; compartment and region matter. Rosmarinic acid reported to reduce copper-induced neurotoxicity in vitro/in vivo and may interfere with amyloid–copper interactions (preclinical). - SAMe↓ concentrations in CSF reported in AD. - MPOD often reduced in AD patients. - AD brains reported lower levels of lutein↓, zeaxanthin↓, anhydrolutein↓, (VitA)retinol↓, lycopene↓, alpha-tocopherol↓. RISK CONTEXT: - Apolipoprotein E4 (ApoE4) genotype is the strongest known genetic risk factor for late-onset AD. - One copy of ApoE4: ~3–4× increased risk (range varies by cohort). - Two copies: ~8–12× increased risk (range varies). - VitK lower in circulating blood of APOE4 carriers (reported). - Type 2 diabetes, traumatic brain injury, stroke, diet, and above all, aging is the number ONE risk factor. Treatments / Strategy Targets (high-level): - Early intervention tends to have a greater positive effect than interventions during middle or late stages. - BOLD fMRI imaging can be used to observe brain activity via blood oxygen/flow changes. - Reduce ROS and inflammation in the brain (context-dependent; avoid over-suppressing adaptive signaling). - Inhibiting acetylcholinesterase (AChE) (which breaks down ACh), e.g., donepezil, rivastigmine. - Natural AChE inhibitors include: Berberine, Luteolin, Crocetin(saffron), Querctin, TQ - Natural AChE inhibitors in database (check BBB pass potential). - MAOB inhibitors, APP inhibitors, PGE2 inhibitors, NLRP3 inhibitors, BACE inhibitors - BDNF activators, PSD95 activator - STEP, ADAM10 - Diets with an adequate ratio (5:1) of omega-6:3 (Mediterranean diet). - Vitamins B1, B6, B12, B9 (folic acid) and D, choline, iron and iodine exert neuroprotective effects (general nutrition framing). - Antioxidants (vitamins C, E, A, zinc, selenium, lutein and zeaxanthin). - Fiber may promote gut microbiome diversity influencing brain health. - Supplementing with NAD⁺ precursors (NR or NMN) improves cognition and reduces amyloid/tau pathologies in AD mice (animal evidence). - "It is advisable to consume diets with an adequate ratio (5:1) of omega-6:3 fatty acids (Mediterranean diet) ... antioxidants ... role in oxidative stress ... cognition." Nutrition Strategies - Reduction of cognitive decline may be achieved by following a healthy dietary pattern limiting added sugars while maximizing fish, fruits, vegetables, nuts, seeds. Related Pathways to research in this database (products that modulate them): - neuroprotective, cognitive, memory - Aβ aggregation, Tau↓, AChE↓, ACh↑, ChAT↑, acetyl-CoA↑, BDNF↑, BACE↓, NLRP3↓, PSD95↑, PGE2↓, homoC↓ - Increasing AntiOxidants: Catalase↑, GSH↑, SOD↑, HO-1↑, to decrease ROS↓ - Lower Inflammation: TNF-α↓, IL1β↓, IL6↓ Natural Products that may benefit AD. -Some key pathways are highlighted in RED in the following links Acetyl-L-carnitine, ALA, Apigenin, Anthocyanins Blueberrys, Aromatherapy, Artemisinin, Ashwagandha, β-carotene(vitamin A), Bacopa monnieri, Baicalein, Baicalin, Berberine, Betulinic acid, Boron, Boswellia (frankincense), Caffeic acid, Caffeine, Capsaicin, Carnosine, Carnosic acid, Chlorogenic acid, Choline, Chrysin, Cinnamon, CoQ10, Crocetin, Curcumin, dietMed, dietMet, dietSTF, EGCG, Ellagic acid, Exercise, Ferulic Acid, Fisetin, Flav, FLS, Folic Acid (5-MTHF, L-methylfolate)-reduce homocysteine, Galantamine, Ginger, Ginkgo biloba, Ginseng, Honokiol, Huperzine A, hydrogen gas, Lecithin, Lutein, Luteolin, Lycopene, M-Blu, Moringa oleifera, Mushroom Lion’s Mane, MSM, MCToil, NAD, Naringenin, PEMF, Piperine, Phenylbutyrate, Phosphatidylserine, Piperlongumine, Potassium, probiotics, Propolis, Pterostilbene, Quercetin, Resveratrol, Rivastigmine, Rosmaric Acid(reduce copper-induced neurotoxicity), Rutin, Safflower yellow, Sage, SAMe, selenium, Serotonin, Shankhpushpi, Shikonin, Shilajit/Fulvic Acid, silicon(reduce Alum bioavialability), Silymarin (Milk Thistle) silibinin, Sulforaphane, Taurine, TQ, Ursolic Acid Vitamin B1, Vitamin B2, Vitamin B3, Vitamin B5, Vitamin B6, Vitamin B12, Vitamin E, Vitamin D, Vitamin K2 Zeaxanthin, zinc, Aluminium has a negative impact on cognition but silicon can decrease Alumunium bioavailability, and Vitamin K2 may provide some protection. Example So does RMF Brain Energy Systems Matrix (AD)Tier 1–2 as “core metabolic cofactors / redox pools”Tier 4 as “alternative fuels / bypass strategies” Tier 5–6 as “capacity + delivery constraints” (often explains why supplements don’t translate)
TSF (Time-Scale Flag): P = 0–30 min, R = 30 min–3 hr, G = >3 hr (adaptation/phenotype). Evidence: "Strong (human)" = consistent clinical/epidemiologic support; "Moderate" = mixed but plausible human signals; "Emerging" = early-stage human; "Mechanistic" = preclinical/biochemical rationale. |
| 4051- | , | Long-term association of food and nutrient intakes with cognitive and functional decline: a 13-year follow-up study of elderly French women |
| - | Study, | AD, | NA |
| 4039- | , | Association of vitamin B12 deficiency in a dementia cohort with hippocampal atrophy on MRI |
| - | Study, | AD, | NA |
| 5303- | 5-HTP, | 5-HTP shows early promise for cognitive support and in seniors: Singapore study |
| - | Trial, | AD, | NA |
| 5298- | 5-HTP, | Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa |
| - | Human, | AD, | NA |
| 5297- | 5-HTP, | Targeting 5-HT Is a Potential Therapeutic Strategy for Neurodegenerative Diseases |
| - | in-vivo, | AD, | NA | - | in-vivo, | Park, | NA |
| 5296- | 5-HTP, | Serotonergic Regulation in Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 5293- | 5-HTP, | The Role of Tryptophan Metabolism in Alzheimer’s Disease |
| - | in-vivo, | AD, | NA |
| 5292- | 5-HTP, | Past, present, and future of serotonin-targeting therapeutics for Alzheimer’s disease: Perspectives from DNA methylation |
| - | Review, | AD, | NA |
| 5289- | 5-HTP, | 5-Hydroxytryptophan (5-HTP): Natural Occurrence, Analysis, Biosynthesis, Biotechnology, Physiology and Toxicology |
| - | Review, | AD, | NA | - | Review, | Arthritis, | NA |
| 5288- | 5-HTP, | The Impact of 5-Hydroxytryptophan Supplementation on Cognitive Function and Mood in Singapore Older Adults: A Randomized Controlled Trial |
| - | Trial, | AD, | NA |
| 5304- | 5-HTP, | Serotoninergic System in Dementia of the Alzheimer Type |
| - | Human, | AD, | NA |
| 5306- | 5-HTP, | Tryptophan-enriched diet or 5-hydroxytryptophan supplementation given in a randomized controlled trial impacts social cognition on a neural and behavioral level |
| - | Trial, | AD, | NA |
| 5299- | 5-HTP, | Serotonin Syndrome from 5-Hydroxytryptophan Supplement Ingestion in a 9-Month-Old Labrador Retriever |
| - | Case Report, | AD, | NA |
| 3940- | 5HT, | Role of serotonin in Alzheimer's disease: a new therapeutic target? |
| - | Review, | AD, | NA |
| 3941- | 5HT, | dietMed, | VitB12, | FA, | VitC | Nutrition strategies that improve cognitive function |
| - | Review, | AD, | NA |
| - | in-vivo, | AD, | NA |
| 3968- | ACNs, | Enhanced Neuronal Activation with Blueberry Supplementation in Mild Cognitive Impairment |
| - | Human, | AD, | NA |
| 3969- | ACNs, | Blueberry Supplementation in Midlife for Dementia Risk Reduction |
| - | Human, | AD, | NA |
| 3971- | ACNs, | Blueberry Supplementation Improves Memory in Older Adults |
| - | Human, | AD, | NA |
| 3972- | ACNs, | Recent Research on the Health Benefits of Blueberries and Their Anthocyanins |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3973- | ACNs, | Saskatoon and wild blueberries have higher anthocyanin contents than other Manitoba berries |
| - | Analysis, | AD, | NA |
| 3865- | ACNs, | Consumption of anthocyanin-rich cherry juice for 12 weeks improves memory and cognition in older adults with mild-to-moderate dementia |
| - | Human, | AD, | NA |
| 3864- | ACNs, | Anthocyanins Potentially Contribute to Defense against Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 4163- | ACNs, | Flav, | Dietary levels of pure flavonoids improve spatial memory performance and increase hippocampal brain-derived neurotrophic factor |
| - | in-vivo, | AD, | NA |
| 2558- | AL, | Allicin, an Antioxidant and Neuroprotective Agent, Ameliorates Cognitive Impairment |
| - | Review, | AD, | NA |
| 2645- | AL, | Allicin improves endoplasmic reticulum stress-related cognitive deficits via PERK/Nrf2 antioxidative signaling pathway |
| - | NA, | AD, | NA |
| 2657- | AL, | Allicin pharmacology: Common molecular mechanisms against neuroinflammation and cardiovascular diseases |
| - | Review, | CardioV, | NA | - | Review, | AD, | NA |
| 2660- | AL, | Allicin: A review of its important pharmacological activities |
| - | Review, | AD, | NA | - | Review, | Var, | NA | - | Review, | Park, | NA | - | Review, | Stroke, | NA |
| 297- | ALA, | Insights on the Use of α-Lipoic Acid for Therapeutic Purposes |
| - | Review, | BC, | SkBr3 | - | Review, | neuroblastoma, | SK-N-SH | - | Review, | AD, | NA |
| 3269- | ALA, | Sulfur-containing therapeutics in the treatment of Alzheimer’s disease |
| - | NA, | AD, | NA |
| 3270- | ALA, | Alpha-lipoic acid as a new treatment option for Alzheimer's disease--a 48 months follow-up analysis |
| - | Trial, | AD, | NA |
| 3271- | ALA, | Decrypting the potential role of α-lipoic acid in Alzheimer's disease |
| - | Review, | AD, | NA |
| 3272- | ALA, | Alpha-lipoic acid as a dietary supplement: Molecular mechanisms and therapeutic potential |
| - | Review, | AD, | NA |
| 3438- | ALA, | The Potent Antioxidant Alpha Lipoic Acid |
| - | Review, | NA, | NA | - | Review, | AD, | NA |
| 3440- | ALA, | Protective effects of alpha lipoic acid (ALA) are mediated by hormetic mechanisms |
| - | Review, | AD, | NA |
| 3441- | ALA, | α-Lipoic Acid Maintains Brain Glucose Metabolism via BDNF/TrkB/HIF-1α Signaling Pathway in P301S Mice |
| - | in-vivo, | AD, | NA |
| 3443- | ALA, | Molecular and Therapeutic Insights of Alpha-Lipoic Acid as a Potential Molecule for Disease Prevention |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 3449- | ALA, | Alpha-Lipoic Acid Downregulates IL-1β and IL-6 by DNA Hypermethylation in SK-N-BE Neuroblastoma Cells |
| - | in-vitro, | AD, | SK-N-BE |
| 3447- | ALA, | Redox Active α-Lipoic Acid Differentially Improves Mitochondrial Dysfunction in a Cellular Model of Alzheimer and Its Control Cells |
| - | in-vitro, | AD, | SH-SY5Y |
| 3551- | ALA, | Alpha lipoic acid treatment in late middle age improves cognitive function: Proteomic analysis of the protective mechanisms in the hippocampus |
| - | in-vivo, | AD, | NA |
| 3539- | ALA, | Alpha-lipoic acid as a dietary supplement: Molecular mechanisms and therapeutic potential |
| - | Review, | AD, | NA |
| 3543- | ALA, | The Effect of Lipoic Acid Therapy on Cognitive Functioning in Patients with Alzheimer's Disease |
| - | Study, | AD, | NA |
| 3552- | ALA, | The dietary fatty acids α-linolenic acid (ALA) and linoleic acid (LA) selectively inhibit microglial nitric oxide production |
| - | in-vitro, | AD, | BV2 |
| 3550- | ALA, | Mitochondrial Dysfunction and Alpha-Lipoic Acid: Beneficial or Harmful in Alzheimer's Disease? |
| - | Review, | AD, | NA |
| 3549- | ALA, | Important roles of linoleic acid and α-linolenic acid in regulating cognitive impairment and neuropsychiatric issues in metabolic-related dementia |
| - | Review, | AD, | NA |
| 3548- | ALA, | How Alpha Linolenic Acid May Sustain Blood–Brain Barrier Integrity and Boost Brain Resilience against Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 3547- | ALA, | Potential Therapeutic Effects of Lipoic Acid on Memory Deficits Related to Aging and Neurodegeneration |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3546- | ALA, | Cognitive and Mood Effect of Alpha-Lipoic Acid Supplementation in a Nonclinical Elder Sample: An Open-Label Pilot Study |
| - | Study, | AD, | NA |
| 3545- | ALA, | Potential therapeutic effects of alpha lipoic acid in memory disorders |
| - | Review, | AD, | NA |
| 3544- | ALA, | Alpha lipoic acid for dementia |
| - | Review, | AD, | NA |
| 3974- | ALC, | Carnitine |
| - | Review, | AD, | NA |
| 3975- | ALC, | Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease |
| - | Trial, | AD, | NA |
| 3976- | ALC, | Acetyl-L-carnitine for dementia |
| - | Review, | AD, | NA |
| 3859- | ALC, | Alpha-Secretase ADAM10 Regulation: Insights into Alzheimer’s Disease Treatment |
| - | Review, | AD, | NA |
| 5262- | aLinA, | The Role of Alpha-Linolenic Acid and Other Polyunsaturated Fatty Acids in Mental Health: A Narrative Review |
| - | Review, | AD, | NA |
| 4124- | Alum, | The potential influence of silica present in drinking water on Alzheimer's disease and associated disorders |
| - | Review, | AD, | NA |
| 4130- | Alum, | Silica and aluminum in drinking water and cognitive impairment in the elderly |
| - | Study, | AD, | NA |
| 4132- | Alum, | Relation between aluminum concentrations in drinking water and Alzheimer's disease: an 8-year follow-up study |
| - | Study, | AD, | NA |
| 4135- | Alum, | Aluminum Should Now Be Considered a Primary Etiological Factor in Alzheimer's Disease |
| - | Review, | AD, | NA |
| 4281- | Api, | The neurotrophic activities of brain‐derived neurotrophic factor are potentiated by binding with apigenin, a common flavone in vegetables, in stimulating the receptor signaling |
| - | in-vitro, | AD, | SH-SY5Y |
| 4280- | Api, | Protective effects of apigenin in neurodegeneration: An update on the potential mechanisms |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3887- | Api, | The flavonoid apigenin protects brain neurovascular coupling against amyloid-β₂₅₋₃₅-induced toxicity in mice |
| - | in-vivo, | AD, | NA |
| 3886- | Api, | Neuroprotective effects of apigenin against inflammation, neuronal excitability and apoptosis in an induced pluripotent stem cell model of Alzheimer’s disease |
| - | in-vitro, | AD, | NA |
| 3885- | Api, | Anti-Inflammatory and Neuroprotective Effect of Apigenin: Studies in the GFAP-IL6 Mouse Model of Chronic Neuroinflammation |
| - | in-vivo, | AD, | NA |
| 3884- | Api, | Neuroprotective, Anti-Amyloidogenic and Neurotrophic Effects of Apigenin in an Alzheimer’s Disease Mouse Model |
| - | in-vivo, | AD, | NA |
| 3883- | Api, | New approach to clearing toxic waste from brain |
| - | Review, | AD, | NA |
| 3882- | Api, | Enhancing Amyloid-β Clearance May Improve Brain Function in Alzheimer Disease |
| - | Review, | AD, | NA |
| 3817- | Aroma, | Therapeutic potential of aromatic plant extracts in Alzheimer's disease: Comprehensive review of their underlying mechanisms |
| - | Review, | AD, | NA |
| 3818- | Aroma, | The effect of inhaled aromatherapy on cognitive function in patients with cognitive impairment: A systematic review and meta-analysis |
| - | Review, | AD, | NA |
| 3819- | Aroma, | Aromatherapy improves cognitive dysfunction in senescence-accelerated mouse prone 8 by reducing the level of amyloid beta and tau phosphorylation |
| - | Human, | AD, | NA | - | in-vitro, | AD, | NA |
| 3820- | Aroma, | Effectiveness and Safety of Aromatherapy in Managing Behavioral and Psychological Symptoms of Dementia: A Mixed-Methods Systematic Review |
| - | Review, | AD, | NA |
| 3821- | Aroma, | Neuroprotective and Anti-Aging Potentials of Essential Oils from Aromatic and Medicinal Plants |
| - | Review, | AD, | NA |
| 3822- | Aroma, | Aromatherapy in the treatment of Alzheimer's disease: A systematic review |
| - | Review, | AD, | NA |
| 3823- | Aroma, | Aromatherapy in dementia |
| - | Review, | AD, | NA |
| - | Human, | AD, | NA |
| 3825- | Aroma, | The effects of lemon balm (Melissa officinalis L.) on depression and anxiety in clinical trials: A systematic review and meta-analysis |
| - | Review, | AD, | NA |
| - | Human, | AD, | NA |
| 3665- | ART/DHA, | Artemisinin B Improves Learning and Memory Impairment in AD Dementia Mice by Suppressing Neuroinflammation |
| - | Review, | AD, | NA |
| 3666- | ART/DHA, | Artemisinin Attenuates Amyloid-Induced Brain Inflammation and Memory Impairments by Modulating TLR4/NF-κB Signaling |
| - | NA, | AD, | NA |
| 4303- | Ash, | Ashwagandha (Withania somnifera)—Current Research on the Health-Promoting Activities: A Narrative Review |
| - | Review, | AD, | NA |
| 3668- | Ash, | Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver |
| - | NA, | AD, | NA |
| 3669- | Ash, | Withanamides in Withania somnifera fruit protect PC-12 cells from beta-amyloid responsible for Alzheimer's diseas |
| - | in-vitro, | AD, | PC12 |
| 3670- | Ash, | Neurodegenerative diseases and Withania somnifera (L.): An update |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3687- | Ash, | Role of Withaferin A and Its Derivatives in the Management of Alzheimer’s Disease: Recent Trends and Future Perspectives |
| - | Review, | AD, | NA |
| 3688- | Ash, | Withaferin A Suppresses Beta Amyloid in APP Expressing Cells: Studies for Tat and Cocaine Associated Neurological Dysfunctions |
| - | NA, | AD, | SH-SY5Y |
| 3671- | Ash, | Withania somnifera showed neuroprotective effect and increase longevity in Drosophila Alzheimer’s disease model |
| - | in-vivo, | AD, | NA |
| 5425- | ASTX, | Multiple roles of fucoxanthin and astaxanthin against Alzheimer's disease: Their pharmacological potential and therapeutic insights |
| - | in-vivo, | AD, | NA |
| 4804- | ASTX, | Astaxanthin in cancer therapy and prevention (Review) |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 4813- | ASTX, | Astaxanthin Prevents Oxidative Damage and Cell Apoptosis Under Oxidative Stress Involving the Restoration of Mitochondrial Function |
| - | in-vitro, | AD, | NA |
| 4304- | Ba, | Baicalein inhibits heparin-induced Tau aggregation by initializing non-toxic Tau oligomer formation |
| - | in-vitro, | AD, | NA |
| 2611- | Ba, | Baicalein as a potent neuroprotective agent: A review |
| - | Review, | Nor, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA |
| 2605- | Ba, | BA, | Potential therapeutic effects of baicalin and baicalein |
| - | Review, | Var, | NA | - | Review, | Stroke, | NA | - | Review, | IBD, | NA | - | Review, | Arthritis, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA |
| 2626- | Ba, | Molecular targets and therapeutic potential of baicalein: a review |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Stroke, | NA |
| 4298- | BBR, | Berberine mitigates cognitive decline in an Alzheimer’s Disease Mouse Model by targeting both tau hyperphosphorylation and autophagic clearance |
| - | in-vivo, | AD, | NA |
| - | in-vivo, | AD, | NA |
| 4300- | BBR, | Effect of berberine on cognitive function and β-amyloid precursor protein in Alzheimer’s disease models: a systematic review and meta-analysis |
| - | Review, | AD, | NA |
| 3833- | BBR, | Traditional Chinese Medicine: Role in Reducing β-Amyloid, Apoptosis, Autophagy, Neuroinflammation, Oxidative Stress, and Mitochondrial Dysfunction of Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 3749- | BBR, | Anti-Alzheimer and Antioxidant Activities of Coptidis Rhizoma Alkaloids |
| - | Review, | AD, | NA |
| 3633- | BBR, | LT, | Cro, | QC, | Naturally Occurring Acetylcholinesterase Inhibitors and Their Potential Use for Alzheimer's Disease Therapy |
| - | Review, | AD, | NA |
| 3677- | BBR, | Berberine: A Potential Multipotent Natural Product to Combat Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 3678- | BBR, | Network pharmacology study on the mechanism of berberine in Alzheimer’s disease model |
| - | Review, | AD, | NA |
| 3679- | BBR, | Berberine alleviates Alzheimer's disease by activating autophagy and inhibiting ferroptosis through the JNK-p38MAPK signaling pathway |
| - | in-vivo, | AD, | NA |
| 3680- | BBR, | Network pharmacology reveals that Berberine may function against Alzheimer’s disease via the AKT signaling pathway |
| - | in-vivo, | AD, | NA |
| 3681- | BBR, | The efficacy and mechanism of berberine in improving aging-related cognitive dysfunction: A study based on network pharmacology |
| - | in-vivo, | AD, | NA |
| 3682- | BBR, | Berberine Improves Cognitive Impairment by Simultaneously Impacting Cerebral Blood Flow and β-Amyloid Accumulation in an APP/tau/PS1 Mouse Model of Alzheimer’s Disease |
| - | in-vitro, | AD, | NA |
| 3683- | BBR, | Characterization of the anti-AChE potential and alkaloids in Rhizoma Coptidis from different Coptis species combined with spectrum-effect relationship and molecular docking |
| - | NA, | AD, | NA |
| 3684- | BBR, | Neuroprotective effects of berberine in animal models of Alzheimer’s disease: a systematic review of pre-clinical studies |
| - | Review, | AD, | NA |
| 2689- | BBR, | Berberine protects against glutamate-induced oxidative stress and apoptosis in PC12 and N2a cells |
| - | in-vitro, | Nor, | PC12 | - | in-vitro, | AD, | NA | - | in-vitro, | Stroke, | NA |
| 2679- | BBR, | Berberine Improves Behavioral and Cognitive Deficits in a Mouse Model of Alzheimer’s Disease via Regulation of β-Amyloid Production and Endoplasmic Reticulum Stress |
| - | in-vivo, | AD, | NA |
| 2731- | BetA, | Betulinic Acid for Glioblastoma Treatment: Reality, Challenges and Perspectives |
| - | Review, | GBM, | NA | - | Review, | Park, | NA | - | Review, | AD, | NA |
| 4061- | betaCar, | VitB12, | VitB6, | FA, | VitB3 | Revisiting the Role of Vitamins and Minerals in Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 3986- | betaCar, | VitC, | Editorial: Impact of Diet on Learning, Memory and Cognition |
| - | Review, | AD, | NA |
| 3987- | betaCar, | Lyco, | Carotenoid bioavailability is higher from salads ingested with full-fat than with fat-reduced salad dressings as measured with electrochemical detection |
| - | Trial, | AD, | NA |
| 3988- | betaCar, | Lut, | Zeax, | Effects of egg consumption on carotenoid absorption from co-consumed, raw vegetables |
| - | Trial, | AD, | NA |
| 4083- | betaCar, | Significance of vitamin A to brain function, behavior and learning |
| - | Review, | AD, | NA |
| 4082- | betaCar, | Marginal vitamin A deficiency facilitates Alzheimer's pathogenesis |
| - | Study, | AD, | NA |
| 4080- | betaCar, | Vitamin A and Alzheimer's disease |
| - | Review, | AD, | NA |
| 4078- | betaCar, | VitC, | VitB6, | Impact of Diet on Learning, Memory and Cognition |
| - | Review, | AD, | NA |
| 3694- | BM, | Use of Bacopa monnieri in the Treatment of Dementia Due to Alzheimer Disease: Systematic Review of Randomized Controlled Trials |
| - | Review, | AD, | NA |
| 3693- | BM, | Bacopa monnieri prevents colchicine-induced dementia by anti-inflammatory action |
| - | in-vivo, | AD, | NA |
| 3698- | BM, | Bacopa monniera prevents from aluminium neurotoxicity in the cerebral cortex of rat brain |
| - | in-vivo, | AD, | NA |
| 3695- | BM, | Bacopa monnieri (L.) wettst. Extract protects against glutamate toxicity and increases the longevity of Caenorhabditis elegans |
| - | in-vitro, | AD, | HT22 |
| 3697- | BM, | Bacopa monnieri, a Neuroprotective Lead in Alzheimer Disease: A Review on Its Properties, Mechanisms of Action, and Preclinical and Clinical Studies |
| - | Review, | AD, | NA |
| 3692- | BM, | Brahmi (Bacopa monnieri): An ayurvedic herb against the Alzheimer's disease |
| - | Review, | AD, | NA |
| 3690- | BM, | Neurocognitive Effect of Nootropic Drug Brahmi (Bacopa monnieri) in Alzheimer's Disease |
| - | Review, | AD, | NA |
| 5478- | BM, | A systematic review of the safety and efficacy on cognitive function of herbal and nutritional medicines in older adults with and without subjective cognitive impairment |
| - | Review, | AD, | NA |
| 5479- | BM, | Importance of high-quality evidence regarding the use of Bacopa monnieri in dementia |
| - | Review, | AD, | NA |
| 5483- | BM, | The Role of Bacopa monnieri in Alzheimer’s Disease: Mechanisms and Potential Clinical Use—A Review |
| - | Review, | AD, | NA |
| 5484- | BM, | The Neurocognitive Effects of Bacopa monnieri and Cognitive Training on Markers of Brain Microstructure in Healthy Older Adults |
| - | in-vivo, | AD, | NA |
| 5485- | BM, | Comparative effects of Bacopa monnieri and Ginkgo biloba on cognitive functions: A systematic review and network meta-analysis |
| - | Review, | AD, | NA |
| 5473- | BM, | Bacopa monnieri: Preclinical and Clinical Evidence of Neuroactive Effects, Safety of Use and the Search for Improved Bioavailability |
| - | in-vivo, | AD, | NA | - | in-vivo, | Park, | NA |
| 760- | Bor, | Therapeutic Efficacy of Boric Acid Treatment on Brain Tissue and Cognitive Functions in Rats with Experimental Alzheimer’s Disease |
| - | in-vivo, | AD, | NA |
| 3518- | Bor, | Boron Report |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 3514- | Bor, | CUR, | Effects of Curcumin and Boric Acid Against Neurodegenerative Damage Induced by Amyloid Beta |
| - | in-vivo, | AD, | NA |
| 3786- | Bor, | New and potential boron-containing compounds for treatment of Alzheimer's disease and cancers |
| - | Analysis, | AD, | NA | - | Analysis, | Var, | NA |
| 3785- | Bor, | Discovery of boron-containing compounds as Aβ aggregation inhibitors and antioxidants for the treatment of Alzheimer's disease |
| - | Analysis, | AD, | NA |
| 3866- | Bos, | Mechanistic role of boswellic acids in Alzheimer's disease: Emphasis on anti-inflammatory properties |
| - | Review, | AD, | NA |
| 4270- | Bos, | Boswellic acids ameliorate neurodegeneration induced by AlCl3: the implication of Wnt/β-catenin pathway |
| - | in-vivo, | AD, | NA |
| 2775- | Bos, | The journey of boswellic acids from synthesis to pharmacological activities |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | PSA, | NA |
| 2768- | Bos, | Boswellic acids as promising agents for the management of brain diseases |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA |
| 2772- | Bos, | Mechanistic role of boswellic acids in Alzheimer’s disease: Emphasis on anti-inflammatory properties |
| - | Review, | AD, | NA |
| - | Analysis, | AD, | NA |
| 3791- | CA, | Caffeic Acid and Diseases—Mechanisms of Action |
| - | Review, | AD, | NA |
| - | Study, | AD, | NA |
| 4263- | CA, | Neuroprotective Effects of Carnosic Acid: Insight into Its Mechanisms of Action |
| - | Review, | AD, | NA |
| 4161- | Caff, | Chronic caffeine prevents changes in inhibitory avoidance memory and hippocampal BDNF immunocontent in middle-aged rats |
| - | in-vivo, | AD, | NA |
| 3854- | CAP, | Capsaicin consumption reduces brain amyloid-beta generation and attenuates Alzheimer’s disease-type pathology and cognitive deficits in APP/PS1 mice |
| - | in-vivo, | AD, | NA |
| 3855- | CAP, | Capsaicin consumption reduces brain amyloid-beta generation and attenuates Alzheimer’s disease-type pathology and cognitive deficits in APP/PS1 mice |
| - | in-vivo, | AD, | NA |
| 2349- | CAP, | The TRPV1-PKM2-SREBP1 axis maintains microglial lipid homeostasis in Alzheimer’s disease |
| - | in-vivo, | AD, | NA |
| 3876- | Carno, | Ex, | Swimming exercise versus L-carnosine supplementation for Alzheimer’s dementia in rats: implication of circulating and hippocampal FNDC5/irisin |
| - | in-vivo, | AD, | NA |
| - | in-vitro, | AD, | NA |
| 3874- | Carno, | Effects of zinc and carnosine on aggregation kinetics of Amyloid-β40 peptide |
| - | Review, | AD, | NA |
| 3877- | Carno, | Carnosine, diabetes and Alzheimer's disease |
| - | Review, | AD, | NA |
| 3879- | Carno, | Daily Carnosine and Anserine Supplementation Alters Verbal Episodic Memory and Resting State Network Connectivity in Healthy Elderly Adults |
| - | Human, | AD, | NA |
| 3873- | Carno, | Effects of dietary supplementation of carnosine on mitochondrial dysfunction, amyloid pathology, and cognitive deficits in 3xTg-AD mice |
| - | in-vivo, | AD, | NA |
| 3870- | Carno, | Could carnosine or related structures suppress Alzheimer's disease? |
| - | Review, | AD, | NA |
| 3880- | Carno, | EFFECT OF ANSERINE/CARNOSINE SUPPLEMENTATION ON THE PREVENTION OF ALZHEIMER'S DISEASE IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT |
| - | Trial, | AD, | NA |
| 3881- | Carno, | The Therapeutic Potential of Carnosine/Anserine Supplementation against Cognitive Decline: A Systematic Review with Meta-Analysis |
| - | Review, | AD, | NA |
| 3872- | Carno, | Carnosine Protects Macrophages against the Toxicity of Aβ1-42 Oligomers by Decreasing Oxidative Stress |
| - | in-vitro, | AD, | NA |
| 3869- | Carno, | Carnosine, Small but Mighty—Prospect of Use as Functional Ingredient for Functional Food Formulation |
| - | Review, | AD, | NA | - | Review, | Stroke, | NA |
| 3699- | Chol, | Association of dietary cholesterol and egg intakes with the risk of incident dementia or Alzheimer disease: the Kuopio Ischaemic Heart Disease Risk Factor Study |
| - | Study, | AD, | NA |
| 3701- | Chol, | Lifelong choline supplementation ameliorates Alzheimer's disease pathology and associated cognitive deficits by attenuating microglia activation |
| - | in-vivo, | AD, | NA |
| 3702- | Chol, | Alzheimer's Disease: Targeting the Cholinergic System |
| - | NA, | AD, | NA |
| 3703- | Chol, | Alzheimer's disease. Correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities |
| - | Human, | AD, | NA |
| 3704- | Chol, | Acetylcholine, aging, and Alzheimer's disease |
| - | Review, | AD, | NA |
| 3705- | Chol, | LEC, | Effects of consumption of choline and lecithin on neurological and cardiovascular systems |
| - | Review, | AD, | NA |
| 3889- | Cin, | Orally administrated cinnamon extract reduces β-amyloid oligomerization and corrects cognitive impairment in Alzheimer's disease animal models |
| - | in-vivo, | AD, | NA |
| 3894- | Cin, | Interaction of cinnamaldehyde and epicatechin with tau: implications of beneficial effects in modulating Alzheimer's disease pathogenesis |
| - | in-vitro, | AD, | NA |
| 3888- | Cin, | Cinnamon, a promising prospect towards Alzheimer's disease |
| - | NA, | AD, | NA |
| 3893- | Cin, | Cinnamon extract inhibits tau aggregation associated with Alzheimer's disease in vitro |
| - | Review, | AD, | NA |
| - | Review, | AD, | NA | - | Review, | Var, | NA |
| 3891- | Cin, | Identification of potential targets of cinnamon for treatment against Alzheimer's disease-related GABAergic synaptic dysfunction using network pharmacology |
| - | Analysis, | AD, | NA |
| 4258- | CoQ10, | Neuroprotective effects of coenzyme Q10-loaded exosomes obtained from adipose-derived stem cells in a rat model of Alzheimer's disease |
| - | in-vivo, | AD, | NA |
| 3997- | CoQ10, | Coenzyme Q and Its Role in the Dietary Therapy against Aging |
| - | Review, | AD, | NA |
| 3994- | CoQ10, | Se, | Coenzyme Q10 Supplementation in Aging and Disease |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3993- | CoQ10, | Coenzyme Q10 Decreases Amyloid Pathology and Improves Behavior in a Transgenic Mouse Model of Alzheimer’s Disease |
| - | Review, | Park, | NA | - | Review, | AD, | NA |
| 3992- | CoQ10, | Coenzyme Q10 |
| - | Review, | AD, | NA |
| 3991- | CoQ10, | Evaluation of Coenzyme Q as an Antioxidant Strategy for Alzheimer’s Disease |
| - | in-vivo, | AD, | NA |
| 3990- | CoQ10, | Serum levels of coenzyme Q10 in patients with Alzheimer's disease |
| - | Study, | AD, | NA |
| 3636- | Cro, | Saffron as a source of novel acetylcholinesterase inhibitors: molecular docking and in vitro enzymatic studies |
| - | in-vitro, | AD, | NA |
| 3624- | Cro, | Crocus Sativus L. (Saffron) in Alzheimer's Disease Treatment: Bioactive Effects on Cognitive Impairment |
| - | Review, | AD, | NA |
| 3625- | Cro, | Saffron in the treatment of patients with mild to moderate Alzheimer's disease: a 16-week, randomized and placebo-controlled trial |
| - | Trial, | AD, | NA |
| 3626- | Cro, | Comparing the efficacy and safety of Crocus sativus L. with memantine in patients with moderate to severe Alzheimer's disease: a double-blind randomized clinical trial |
| - | Trial, | AD, | NA |
| 3627- | Cro, | The effects of Crocus sativus (saffron) and its constituents on nervous system: A review |
| - | Review, | AD, | NA | - | Review, | Stroke, | NA |
| 3628- | Cro, | VitE, | CUR, | Vitamin E, Turmeric and Saffron in Treatment of Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 3630- | Cro, | Crocin Improves Cognitive Behavior in Rats with Alzheimer's Disease by Regulating Endoplasmic Reticulum Stress and Apoptosis |
| - | in-vivo, | AD, | NA |
| 3631- | Cro, | Investigation of the neuroprotective effects of crocin via antioxidant activities in HT22 cells and in mice with Alzheimer's disease |
| - | in-vitro, | AD, | HT22 | - | in-vivo, | AD, | NA |
| 3634- | Cro, | A 22-week, multicenter, randomized, double-blind controlled trial of Crocus sativus in the treatment of mild-to-moderate Alzheimer's disease |
| - | Trial, | AD, | NA |
| 3637- | Cro, | Investigation of the neuroprotective action of saffron (Crocus sativus L.) in aluminum-exposed adult mice through behavioral and neurobiochemical assessment |
| - | NA, | AD, | NA |
| 3832- | Cro, | Traditional Chinese Medicine: Role in Reducing β-Amyloid, Apoptosis, Autophagy, Neuroinflammation, Oxidative Stress, and Mitochondrial Dysfunction of Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 4158- | Cro, | Antidepressant effects of crocin and its effects on transcript and protein levels of CREB, BDNF, and VGF in rat hippocampus |
| - | in-vivo, | AD, | NA |
| - | in-vivo, | AD, | NA |
| 3753- | CUR, | Gala, | A Novel Galantamine–Curcumin Hybrid Inhibits Butyrylcholinesterase: A Molecular Dynamics Study |
| - | Study, | AD, | NA |
| 3794- | CUR, | Curcumin hybrid molecules for the treatment of Alzheimer's disease: Structure and pharmacological activities |
| - | Review, | AD, | NA |
| 3752- | CUR, | Revealing the molecular interplay of curcumin as Culex pipiens Acetylcholine esterase 1 (AChE1) inhibitor |
| - | in-vivo, | AD, | NA |
| 3751- | CUR, | Gala, | A Novel Galantamine-Curcumin Hybrid as a Potential Multi-Target Agent against Neurodegenerative Disorders |
| - | in-vivo, | AD, | NA |
| - | in-vitro, | AD, | SH-SY5Y |
| 3748- | CUR, | RES, | Hup, | Riv, | Gala | Natural acetylcholinesterase inhibitors: A multi-targeted therapeutic potential in Alzheimer's disease |
| - | Review, | AD, | NA |
| 3831- | CUR, | Traditional Chinese Medicine: Role in Reducing β-Amyloid, Apoptosis, Autophagy, Neuroinflammation, Oxidative Stress, and Mitochondrial Dysfunction of Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 3860- | CUR, | Curcumin Ameliorates Memory Decline via Inhibiting BACE1 Expression and β-Amyloid Pathology in 5×FAD Transgenic Mice |
| - | in-vivo, | AD, | NA |
| 3793- | CUR, | Curcumin Downregulates GSK3 and Cdk5 in Scopolamine-Induced Alzheimer’s Disease Rats Abrogating Aβ40/42 and Tau Hyperphosphorylation |
| - | in-vivo, | AD, | NA |
| 3795- | CUR, | Curcumin: A Golden Approach to Healthy Aging: A Systematic Review of the Evidence |
| - | Review, | AD, | NA |
| 3856- | CUR, | Curcumin induces IL-6 receptor shedding via the ADAM10 proteinase |
| - | in-vitro, | AD, | NA |
| 3862- | CUR, | RES, | The metalloproteinase ADAM10: A useful therapeutic target? |
| - | Review, | AD, | NA |
| 3857- | CUR, | Alpha-Secretase ADAM10 Regulation: Insights into Alzheimer’s Disease Treatment |
| - | Review, | AD, | NA |
| 3590- | CUR, | The Holy Grail of Curcumin and its Efficacy in Various Diseases: Is Bioavailability Truly a Big Concern? |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 3588- | CUR, | The effect of curcumin on cognition in Alzheimer’s disease and healthy aging: A systematic review of pre-clinical and clinical studies |
| - | Review, | AD, | NA |
| 3581- | CUR, | Curcumin Attenuated Neurotoxicity in Sporadic Animal Model of Alzheimer's Disease |
| - | NA, | AD, | NA |
| 3580- | CUR, | Curcumin Acts as Post-protective Effects on Rat Hippocampal Synaptosomes in a Neuronal Model of Aluminum-Induced Toxicity |
| - | in-vivo, | AD, | NA |
| 3577- | CUR, | Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study |
| - | Trial, | AD, | NA |
| 3576- | CUR, | Protective Effects of Indian Spice Curcumin Against Amyloid-β in Alzheimer's Disease |
| - | Review, | AD, | NA |
| 3575- | CUR, | The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse |
| - | in-vivo, | AD, | NA |
| 3574- | CUR, | The effect of curcumin (turmeric) on Alzheimer's disease: An overview |
| - | Review, | AD, | NA |
| 2688- | CUR, | Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 2818- | CUR, | Novel Insight to Neuroprotective Potential of Curcumin: A Mechanistic Review of Possible Involvement of Mitochondrial Biogenesis and PI3/Akt/ GSK3 or PI3/Akt/CREB/BDNF Signaling Pathways |
| - | Review, | AD, | NA |
| 2816- | CUR, | NEUROPROTECTIVE EFFECTS OF CURCUMIN |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 4333- | Cyste, | Cystamine protects from 3-nitropropionic acid lesioning via induction of nf-e2 related factor 2 mediated transcription |
| - | vitro+vivo, | AD, | NA |
| 4331- | Cyste, | Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase |
| - | in-vivo, | HD, | NA | - | NA, | AD, | NA |
| 5071- | dietSTF, | Unraveling the impact of intermittent fasting in cancer prevention, mitigation, and treatment: A narrative review |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 4159- | dietSTF, | 2DG, | CRMs, | Meal size and frequency affect neuronal plasticity and vulnerability to disease: cellular and molecular mechanisms |
| - | Review, | AD, | NA |
| 3707- | dietSTF, | Intermittent fasting protects against the deterioration of cognitive function, energy metabolism and dyslipidemia in Alzheimer’s disease-induced estrogen deficient rats |
| - | in-vivo, | AD, | NA |
| 3709- | dietSTF, | Intermittent Fasting Protects against Alzheimer’s Disease Possible through Restoring Aquaporin-4 Polarity |
| - | in-vitro, | AD, | NA |
| 3756- | EA, | Acetylcholinesterase and monoamine oxidase-B inhibitory activities by ellagic acid derivatives isolated from Castanopsis cuspidata var. sieboldii |
| - | Analysis, | AD, | NA |
| 3232- | EGCG, | (−)-Epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer׳s disease model mice by upregulating neprilysin expression |
| - | in-vivo, | AD, | NA |
| 3237- | EGCG, | (-)-Epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer's disease model mice by upregulating neprilysin expression |
| - | in-vivo, | AD, | NA |
| 3205- | EGCG, | The Role of Epigallocatechin-3-Gallate in Autophagy and Endoplasmic Reticulum Stress (ERS)-Induced Apoptosis of Human Diseas |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 4152- | EGCG, | Green tea catechins potentiate the neuritogenic action of brain-derived neurotrophic factor: role of 67-kDa laminin receptor and hydrogen peroxide |
| - | in-vitro, | AD, | NA |
| 3594- | EGCG, | Epigallocatechin-3-gallate inhibits secretion of TNF-alpha, IL-6 and IL-8 through the attenuation of ERK and NF-kappaB in HMC-1 cells |
| - | in-vitro, | AD, | HMC1 |
| 3591- | EGCG, | Epigallocatechin-3-Gallate Provides Protection Against Alzheimer's Disease-Induced Learning and Memory Impairments in Rats |
| - | in-vivo, | AD, | NA |
| 3592- | EGCG, | (-)-Epigallocatechin-3-gallate ameliorates memory impairment and rescues the abnormal synaptic protein levels in the frontal cortex and hippocampus in a mouse model of Alzheimer's disease |
| - | in-vivo, | AD, | NA |
| 3593- | EGCG, | Epigallocatechin Gallate (EGCG) |
| - | Review, | AD, | NA |
| 4290- | EGCG, | EGCG impedes human Tau aggregation and interacts with Tau |
| - | in-vitro, | AD, | NA |
| 4291- | EGCG, | Structure-based discovery of small molecules that disaggregate Alzheimer’s disease tissue derived tau fibrils in vitro |
| - | in-vitro, | AD, | NA |
| 2345- | EMD, | Emodin ameliorates antioxidant capacity and exerts neuroprotective effect via PKM2-mediated Nrf2 transactivation |
| - | in-vitro, | AD, | PC12 |
| 3830- | EMD, | Traditional Chinese Medicine: Role in Reducing β-Amyloid, Apoptosis, Autophagy, Neuroinflammation, Oxidative Stress, and Mitochondrial Dysfunction of Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 3985- | Ex, | The combined effect of physical activity and fruit and vegetable intake on decreasing cognitive decline in older Taiwanese adults |
| - | Study, | AD, | NA |
| 4140- | Ex, | Experimental and clinical evidence of physical exercise on BDNF and cognitive function: A comprehensive review from molecular basis to therapy |
| - | Review, | AD, | NA |
| 4155- | Ex, | Prior regular exercise reverses the decreased effects of sleep deprivation on brain-derived neurotrophic factor levels in the hippocampus of ovariectomized female rats |
| - | in-vivo, | AD, | NA |
| 4137- | Ex, | The impact of exercise on patients with dementia |
| - | Trial, | AD, | NA |
| 4138- | Ex, | Relationship Between Exercise and Alzheimer’s Disease: A Narrative Literature Review |
| - | Review, | AD, | NA |
| 4139- | Ex, | Impact of physical exercise on the regulation of brain-derived neurotrophic factor in people with neurodegenerative diseases |
| - | Review, | AD, | NA |
| 4141- | Ex, | Effects of exercise on brain-derived neurotrophic factor in Alzheimer's disease models: A systematic review and meta-analysis |
| - | Review, | AD, | NA |
| 4142- | Ex, | Mechanisms of the Beneficial Effects of Exercise on Brain-Derived Neurotrophic Factor Expression in Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 4143- | Ex, | Brain-Derived Neurotrophic Factor: A Connecting Link Between Nutrition, Lifestyle, and Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 4144- | Ex, | Exploring the impact of exercise-induced BDNF on neuroplasticity in neurodegenerative and neuropsychiatric conditions |
| - | Review, | AD, | NA |
| 4145- | Ex, | Effects of different physical activities on brain-derived neurotrophic factor: A systematic review and bayesian network meta-analysis |
| - | Review, | AD, | NA |
| 4073- | FA, | The importance of folic acid deficiency in the pathogenesis of vascular, mixed and Alzheimer's disease dementia |
| - | Study, | AD, | NA |
| 4068- | FA, | Hyperhomocysteinemia in Alzheimer's disease: the hen and the egg? |
| - | in-vivo, | AD, | NA |
| 4069- | FA, | Folate, folic acid and 5-methyltetrahydrofolate are not the same thing |
| - | Review, | AD, | NA |
| 4070- | FA, | Folic Acid Supplementation Mitigates Alzheimer's Disease by Reducing Inflammation: A Randomized Controlled Trial |
| - | Trial, | AD, | NA |
| 4071- | FA, | Folate and Alzheimer: when time matters |
| - | Review, | AD, | NA |
| 4072- | FA, | Folic acid with or without vitamin B12 for cognition and dementia |
| - | Review, | AD, | NA |
| 4064- | FA, | VitB6, | VitB12, | High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial |
| - | Trial, | AD, | NA |
| 4076- | FA, | VitE, | VitB6, | Reduced risk of Alzheimer’s disease with high folate intake: The Baltimore Longitudinal Study of Aging |
| - | Study, | AD, | NA |
| 4075- | FA, | Folic acid, ageing, depression, and dementia |
| - | Review, | AD, | NA |
| 4074- | FA, | VitB12, | Associations between Alzheimer's disease and blood homocysteine, vitamin B12, and folate: a case-control study |
| - | Trial, | AD, | NA |
| 3783- | FA, | Design, Synthesis, and Biological Evaluation of Ferulic Acid-Piperazine Derivatives Targeting Pathological Hallmarks of Alzheimer’s Disease |
| - | NA, | AD, | NA |
| 3782- | FA, | Ferulic acid ameliorates bisphenol A (BPA)-induced Alzheimer’s disease-like pathology through Akt-ERK crosstalk pathway in male rats |
| - | in-vivo, | AD, | NA |
| 3781- | FA, | Therapeutic potential of ferulic acid and its derivatives in Alzheimer’s disease—A systematic review |
| - | Review, | AD, | NA |
| 3780- | FA, | Ferulic Acid: A Natural Antioxidant with Application Towards Neuroprotection Against Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 3779- | FA, | A review on ferulic acid and analogs based scaffolds for the management of Alzheimer’s disease |
| - | Review, | AD, | NA |
| 3778- | FA, | Recent Advances in the Neuroprotective Properties of Ferulic Acid in Alzheimer’s Disease: A Narrative Review |
| - | Review, | AD, | NA |
| 4059- | FA, | Dietary B Vitamins and a 10-Year Risk of Dementia in Older Persons |
| - | Study, | AD, | NA |
| 4044- | FA, | Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial |
| - | Trial, | AD, | NA |
| 3710- | FA, | Therapeutic Potential of Ferulic Acid in Alzheimer's Disease |
| - | Review, | AD, | NA |
| 3711- | FA, | A review on ferulic acid and analogs based scaffolds for the management of Alzheimer's disease |
| - | Review, | AD, | NA |
| 3712- | FA, | Ferulic Acid: A Hope for Alzheimer’s Disease Therapy from Plants |
| - | Review, | AD, | NA |
| 3713- | FA, | Protective Effect of Ferulic Acid on Acetylcholinesterase and Amyloid Beta Peptide Plaque Formation in Alzheimer’s Disease: An In Vitro Study |
| - | Review, | AD, | NA |
| 3714- | FA, | Recent Advances in the Neuroprotective Properties of Ferulic Acid in Alzheimer's Disease: A Narrative Review |
| - | Review, | AD, | NA |
| 3715- | FA, | CUR, | PS, | The Additive Effects of Low Dose Intake of Ferulic Acid, Phosphatidylserine and Curcumin, Not Alone, Improve Cognitive Function in APPswe/PS1dE9 Transgenic Mice |
| - | in-vivo, | AD, | NA |
| 3717- | FA, | Neuroprotective Properties of Ferulic Acid in Preclinical Models of Alzheimer's Disease: A Systematic Literature Review |
| - | Review, | AD, | NA |
| 3718- | FA, | Therapeutic potential of ferulic acid and its derivatives in Alzheimer's disease-A systematic review |
| - | Review, | AD, | NA |
| 4063- | Flav, | VitB12, | VitB6, | Homocysteine and Dementia: An International Consensus Statement |
| - | Review, | AD, | NA |
| 4060- | Flav, | Vitamin Supplementation and Dementia: A Systematic Review |
| - | Review, | AD, | NA |
| 4107- | FLS, | Ex, | Combined effects of aerobic exercise and 40-Hz light flicker exposure on early cognitive impairments in Alzheimer's disease of 3×Tg mice |
| - | in-vivo, | AD, | NA |
| 4108- | FLS, | Improvement of olfactory function in AD mice mediated by immune responses under 40 Hz light flickering |
| - | in-vivo, | AD, | NA |
| 4121- | FLS, | Sensory-Evoked 40-Hz Gamma Oscillation Improves Sleep and Daily Living Activities in Alzheimer’s Disease Patients |
| - | Trial, | AD, | NA |
| 4025- | FulvicA, | Mumio (Shilajit) as a potential chemotherapeutic for the urinary bladder cancer treatment |
| - | in-vitro, | Bladder, | T24/HTB-9 | - | Review, | AD, | NA |
| 4018- | FulvicA, | Fe, | Inhibitory Impacts of Fulvic Acid-Coated Iron Oxide Nanoparticles on the Amyloid Fibril Aggregations |
| - | in-vivo, | AD, | NA |
| 4017- | FulvicA, | Fulvic acid inhibits aggregation and promotes disassembly of tau fibrils associated with Alzheimer's disease |
| - | NA, | AD, | NA |
| 4019- | FulvicA, | Can nutraceuticals prevent Alzheimer's disease? Potential therapeutic role of a formulation containing shilajit and complex B vitamins |
| - | Review, | AD, | NA |
| 4016- | FulvicA, | Shilajit: A Natural Phytocomplex with Potential Procognitive Activity |
| - | Review, | AD, | NA |
| 4020- | FulvicA, | Natural products as a rich source of tau-targeting drugs for Alzheimer’s disease |
| - | in-vitro, | AD, | NA |
| 4021- | FulvicA, | Scaling the Andean Shilajit: A Novel Neuroprotective Agent for Alzheimer’s Disease |
| - | in-vitro, | AD, | NA |
| 3719- | GABA, | Treatment Options in Alzheimer´s Disease: The GABA Story |
| - | Review, | AD, | NA |
| 3720- | GABA, | Effects of Oral Gamma-Aminobutyric Acid (GABA) Administration on Stress and Sleep in Humans: A Systematic Review |
| - | Review, | AD, | NA |
| 3722- | Gb, | Alzheimer's disease: Research summaries – Do Ginkgo products help? |
| - | Review, | AD, | NA |
| 3723- | Gb, | Can We Use Ginkgo biloba Extract to Treat Alzheimer’s Disease? Lessons from Preclinical and Clinical Studies |
| - | Review, | AD, | NA |
| 3721- | Gb, | Ginkgo biloba Extract in Alzheimer’s Disease: From Action Mechanisms to Medical Practice |
| - | Review, | AD, | NA |
| 4302- | Gins, | Panax ginseng: A modulator of amyloid, tau pathology, and cognitive function in Alzheimer's disease |
| - | Review, | AD, | NA |
| 4301- | Gins, | Red Ginseng Inhibits Tau Aggregation and Promotes Tau Dissociation In Vitro |
| - | in-vitro, | AD, | NA |
| 4243- | Gins, | Effects of Ginseng on Neurological Disorders |
| - | Review, | Stroke, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA |
| 4004- | Gins, | Effects of fermented ginseng on memory impairment and β-amyloid reduction in Alzheimer’s disease experimental models |
| - | in-vivo, | AD, | NA |
| 3998- | Gins, | Ginseng for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
| - | Trial, | AD, | NA |
| 4002- | Gins, | Improvement of cognitive deficit in Alzheimer's disease patients by long term treatment with korean red ginseng |
| - | Trial, | AD, | NA |
| 4001- | Gins, | An open-label trial of Korean red ginseng as an adjuvant treatment for cognitive impairment in patients with Alzheimer's disease |
| - | Human, | AD, | NA |
| 4000- | Gins, | Heat-processed ginseng enhances the cognitive function in patients with moderately severe Alzheimer's disease |
| - | Human, | AD, | NA |
| 3829- | Gins, | Traditional Chinese Medicine: Role in Reducing β-Amyloid, Apoptosis, Autophagy, Neuroinflammation, Oxidative Stress, and Mitochondrial Dysfunction of Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 4306- | H2, | Molecular Hydrogen as an Emerging Candidate for Preventing Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 4307- | H2, | Hydrogen Gas Attenuates Toxic Metabolites and Oxidative Stress-Mediated Signaling to Inhibit Neurodegeneration and Enhance Memory in Alzheimer’s Disease Models |
| - | in-vivo, | AD, | NA |
| 4308- | H2, | A biomimetic upconversion nanoreactors for near-infrared driven H2 release to inhibit tauopathy in Alzheimer's disease therapy |
| - | in-vivo, | AD, | NA |
| 3768- | H2, | Effects of Hydrogen Gas Inhalation on Community-Dwelling Adults of Various Ages: A Single-Arm, Open-Label, Prospective Clinical Trial |
| - | Trial, | AD, | NA |
| 3770- | H2, | Role of Molecular Hydrogen in Ageing and Ageing-Related Diseases |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3761- | H2, | Therapeutic Inhalation of Hydrogen Gas for Alzheimer's Disease Patients and Subsequent Long-Term Follow-Up as a Disease-Modifying Treatment: An Open Label Pilot Study |
| - | Human, | AD, | NA |
| - | Review, | AD, | NA | - | Review, | Stroke, | NA |
| 3772- | H2, | Therapeutic potential of hydrogen-rich water in zebrafish model of Alzheimer’s disease: targeting oxidative stress, inflammation, and the gut-brain axis |
| - | in-vivo, | AD, | NA |
| 3774- | H2, | The role of hydrogen in Alzheimer’s disease |
| - | Review, | AD, | NA |
| 3775- | H2, | Molecular hydrogen therapy for neurological diseases: a review of current evidence |
| - | Review, | AD, | NA | - | Review, | Stroke, | NA |
| 3776- | H2, | The role of hydrogen in Alzheimer's disease |
| - | Review, | AD, | NA |
| 3777- | H2, | Molecular Hydrogen: an Emerging Therapeutic Medical Gas for Brain Disorders |
| - | Review, | AD, | NA | - | Review, | Stroke, | NA | - | Review, | Park, | NA |
| 3787- | H2, | Hydrogen, a Novel Therapeutic Molecule, Regulates Oxidative Stress, Inflammation, and Apoptosis |
| - | Review, | AD, | NA |
| 3762- | H2, | Effects of Molecular Hydrogen Assessed by an Animal Model and a Randomized Clinical Study on Mild Cognitive Impairment |
| - | in-vivo, | AD, | NA |
| 3763- | H2, | Long-Term Inhalation of Hydrogen Gas for Patients with Advanced Alzheimer's Disease: A Case Report Showing Improvement in Fecal Incontinence |
| - | Case Report, | AD, | NA |
| 3764- | H2, | Therapeutic Effects of Hydrogen Gas Inhalation on Trimethyltin-Induced Neurotoxicity and Cognitive Impairment in the C57BL/6 Mice Model |
| - | in-vivo, | AD, | NA |
| 3765- | H2, | Therapeutic Inhalation of Hydrogen Gas for Alzheimer’s Disease Patients and Subsequent Long-Term Follow-Up as a Disease-Modifying Treatment: An Open Label Pilot Study |
| - | Study, | AD, | NA |
| 3766- | H2, | The role of hydrogen in Alzheimer′s disease |
| - | Review, | AD, | NA |
| 3767- | H2, | The role of hydrogen therapy in Alzheimer's disease management: Insights into mechanisms, administration routes, and future challenges |
| - | Review, | AD, | NA |
| 3769- | H2S, | Research progress of hydrogen sulfide in Alzheimer's disease from laboratory to hospital: a narrative review |
| - | Review, | AD, | NA |
| 2872- | HNK, | Honokiol alleviated neurodegeneration by reducing oxidative stress and improving mitochondrial function in mutant SOD1 cellular and mouse models of amyotrophic lateral sclerosis |
| - | in-vivo, | ALS, | NA | - | NA, | Stroke, | NA | - | NA, | AD, | NA | - | NA, | Park, | NA |
| 2869- | HNK, | Nature's neuroprotector: Honokiol and its promise for Alzheimer's and Parkinson's |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 2887- | HNK, | Honokiol Restores Microglial Phagocytosis by Reversing Metabolic Reprogramming |
| - | in-vitro, | AD, | BV2 |
| 2894- | HNK, | Pharmacological features, health benefits and clinical implications of honokiol |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 4238- | HNK, | Neuropharmacological potential of honokiol and its derivatives from Chinese herb Magnolia species: understandings from therapeutic viewpoint |
| - | Review, | AD, | NA | - | NA, | Park, | NA |
| 4210- | Hup, | A Synopsis of Multitarget Potential Therapeutic Effects of Huperzine A in Diverse Pathologies–Emphasis on Alzheimer’s Disease Pathogenesis |
| - | Review, | AD, | NA |
| 3805- | Hup, | Isolation, diversity and acetylcholinesterase inhibitory activity of the culturable endophytic fungi harboured in Huperzia serrata from Jinggang Mountain, China |
| - | Analysis, | AD, | NA |
| 3804- | Hup, | Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials |
| - | Review, | AD, | NA |
| 3803- | Hup, | Huperzine A and Its Neuroprotective Molecular Signaling in Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 3802- | Hup, | New insights into huperzine A for the treatment of Alzheimer's disease |
| - | Review, | AD, | NA |
| 3801- | Hup, | An update on huperzine A as a treatment for Alzheimer's disease |
| - | Review, | AD, | NA |
| 3800- | Hup, | Role of huperzine a in the treatment of Alzheimer's disease |
| - | Review, | AD, | NA |
| 3799- | Hup, | The use of Huperzia species for the treatment of Alzheimer's disease |
| - | NA, | AD, | NA |
| 5113- | JG, | Juglone in Oxidative Stress and Cell Signaling |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 4010- | K+, | Potassium-sparing diuretics might reduce risk of Alzheimer's disease |
| - | Review, | AD, | NA |
| 4012- | K+, | Abnormal potassium-channel function in platelets in Alzheimer's disease |
| - | in-vivo, | AD, | NA |
| 4013- | K+, | Apamin Improves Prefrontal Nicotinic Impairment in Mouse Model of Alzheimer's Disease |
| - | in-vitro, | AD, | NA |
| 4009- | K+, | Na+ and K+ ion imbalances in Alzheimer’s disease |
| - | Human, | AD, | NA |
| 4008- | K+, | Potassium channels in the neuronal homeostasis and neurodegenerative pathways underlying Alzheimer's disease: An update |
| - | Review, | AD, | NA |
| 4007- | K+, | The increased potassium intake improves cognitive performance and attenuates histopathological markers in a model of Alzheimer's disease |
| - | in-vivo, | AD, | NA |
| 4006- | K+, | Rubidium and potassium levels are altered in Alzheimer's disease brain and blood but not in cerebrospinal fluid |
| - | in-vitro, | AD, | NA |
| 3706- | LEC, | Lecithin for dementia and cognitive impairment |
| - | Review, | AD, | NA |
| 4295- | LT, | Luteolin Reduces Alzheimer’s Disease Pathologies Induced by Traumatic Brain Injury |
| - | in-vivo, | AD, | NA |
| 4292- | LT, | Luteolin for neurodegenerative diseases: a review |
| - | Review, | AD, | NA | - | Review, | Park, | NA | - | Review, | MS, | NA | - | Review, | Stroke, | NA |
| 2904- | LT, | Luteolin from Purple Perilla mitigates ROS insult particularly in primary neurons |
| - | in-vitro, | Park, | SK-N-SH | - | in-vitro, | AD, | NA |
| 2916- | LT, | Antioxidative and Anticancer Potential of Luteolin: A Comprehensive Approach Against Wide Range of Human Malignancies |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA |
| 4231- | Lut, | Luteolin and its antidepressant properties: From mechanism of action to potential therapeutic application |
| - | Review, | AD, | NA |
| 3984- | Lut, | VitE, | Serum concentrations of vitamin E and carotenoids are altered in Alzheimer's disease: A case-control study |
| - | Study, | AD, | NA |
| 3977- | Lut, | Zeax, | Dietary carotenoids related to risk of incident Alzheimer dementia (AD) and brain AD neuropathology: a community-based cohort of older adults |
| - | Trial, | AD, | NA |
| 3978- | Lut, | Zeax, | Effects of Lutein/Zeaxanthin Supplementation on the Cognitive Function of Community Dwelling Older Adults: A Randomized, Double-Masked, Placebo-Controlled Trial |
| - | Trial, | AD, | NA |
| 3979- | Lut, | Increases in Plasma Lutein through Supplementation Are Correlated with Increases in Physical Activity and Reductions in Sedentary Time in Older Adults |
| - | Trial, | AD, | NA |
| 3980- | Lut, | Zeax, | Supplementation With Carotenoids, Omega-3 Fatty Acids, and Vitamin E Has a Positive Effect on the Symptoms and Progression of Alzheimer's Disease |
| - | Trial, | AD, | NA |
| 3981- | Lut, | Zeax, | VitE, | Omega-3 fatty acid, carotenoid and vitamin E supplementation improves working memory in older adults: A randomised clinical trial |
| - | Trial, | AD, | NA |
| 3982- | Lut, | Zeax, | Nutritional Intervention to Prevent Alzheimer's Disease: Potential Benefits of Xanthophyll Carotenoids and Omega-3 Fatty Acids Combined |
| - | Trial, | AD, | NA |
| 3983- | Lut, | Zeax, | The impact of supplemental macular carotenoids in Alzheimer's disease: a randomized clinical trial |
| - | Trial, | AD, | NA |
| 4195- | Lut, | Zeax, | Low Xanthophylls, Retinol, Lycopene, and Tocopherols in Grey and White Matter of Brains with Alzheimer’s Disease |
| - | Human, | AD, | NA |
| 3532- | Lyco, | Lycopene alleviates oxidative stress via the PI3K/Akt/Nrf2pathway in a cell model of Alzheimer’s disease |
| - | in-vitro, | AD, | NA |
| 3528- | Lyco, | The Importance of Antioxidant Activity for the Health-Promoting Effect of Lycopene |
| - | Review, | Nor, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3816- | Lyco, | Lut, | Zeax, | Serum lycopene, lutein and zeaxanthin, and the risk of Alzheimer's disease mortality in older adults |
| - | Review, | AD, | NA |
| 3828- | Lyco, | Lycopene alleviates oxidative stress via the PI3K/Akt/Nrf2pathway in a cell model of Alzheimer's disease |
| - | in-vitro, | AD, | M146L |
| 3268- | Lyco, | Lycopene as a Natural Antioxidant Used to Prevent Human Health Disorders |
| - | Review, | AD, | NA |
| 3264- | Lyco, | Pharmacological potentials of lycopene against aging and aging‐related disorders: A review |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Stroke, | NA |
| 4230- | Lyco, | Supplementation of lycopene attenuates oxidative stress induced neuroinflammation and cognitive impairment via Nrf2/NF-κB transcriptional pathway |
| - | in-vivo, | AD, | NA |
| 4229- | Lyco, | Implicating the role of lycopene in restoration of mitochondrial enzymes and BDNF levels in β-amyloid induced Alzheimer׳s disease |
| - | in-vivo, | AD, | NA |
| 4228- | Lyco, | A review for the pharmacological effect of lycopene in central nervous system disorders |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 4789- | Lyco, | Inhibitory Effect of Lycopene on Amyloid-β-Induced Apoptosis in Neuronal Cells |
| - | in-vitro, | AD, | SH-SY5Y |
| 2545- | M-Blu, | Reversing the Warburg Effect as a Treatment for Glioblastoma |
| - | in-vitro, | GBM, | U87MG | - | NA, | AD, | NA | - | in-vitro, | GBM, | A172 | - | in-vitro, | GBM, | T98G |
| 2540- | M-Blu, | Alternative mitochondrial electron transfer for the treatment of neurodegenerative diseases and cancers: Methylene blue connects the dots |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 3902- | MCT, | Effects of Caprylic Triglyceride on Cognitive Performance and Cerebral Glucose Metabolism in Mild Alzheimer’s Disease: A Single-Case Observation |
| - | Case Report, | AD, | NA |
| 3903- | MCT, | Retrospective case studies of the efficacy of caprylic triglyceride in mild-to-moderate Alzheimer’s disease |
| - | Case Report, | AD, | NA |
| 3904- | MCT, | Retrospective cohort study of the efficacy of caprylic triglyceride in patients with mild-to-moderate alzheimer’s disease |
| - | Human, | AD, | NA |
| 3905- | MCT, | Medium Chain Triglycerides induce mild ketosis and may improve cognition in Alzheimer's disease. A systematic review and meta-analysis of human studies |
| - | Review, | AD, | NA |
| 3901- | MCT, | Potential of Capric Acid in Neurological Disorders: An Overview |
| - | Review, | AD, | NA |
| - | in-vitro, | AD, | NA |
| 3899- | MCT, | COCONUT OIL: NON-ALTERNATIVE DRUG TREATMENT AGAINST ALZHEIMER´S DISEASE |
| - | Human, | AD, | NA |
| 3898- | MCT, | Potential of coconut oil and medium chain triglycerides in the prevention and treatment of Alzheimer's disease |
| - | Review, | AD, | NA |
| 3897- | MCT, | The medium-chain fatty acid decanoic acid reduces oxidative stress levels in neuroblastoma cells |
| - | in-vitro, | AD, | NA |
| 3896- | MCT, | Improvement of Main Cognitive Functions in Patients with Alzheimer's Disease after Treatment with Coconut Oil Enriched Mediterranean Diet: A Pilot Study |
| - | Trial, | AD, | NA |
| 3895- | MCT, | How does coconut oil affect cognitive performance in alzheimer patients? |
| - | Human, | AD, | NA |
| 1778- | MEL, | Melatonin: a well-documented antioxidant with conditional pro-oxidant actions |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 2385- | MET, | Metformin activates chaperone-mediated autophagy and improves disease pathologies in an Alzheimer disease mouse model |
| - | in-vitro, | AD, | H4 | - | in-vitro, | NA, | HEK293 | - | in-vivo, | NA, | NA | - | in-vitro, | NA, | SH-SY5Y |
| 4096- | MF, | Extremely Low‐Frequency and Low‐Intensity Electromagnetic Field Technology (ELF‐EMF) Sculpts Microtubules |
| - | in-vitro, | AD, | NA |
| 4105- | MF, | Extremely low frequency electromagnetic fields stimulation modulates autoimmunity and immune responses: a possible immuno-modulatory therapeutic effect in neurodegenerative diseases |
| - | Review, | AD, | NA |
| 4147- | MF, | PEMFs Restore Mitochondrial and CREB/BDNF Signaling in Oxidatively Stressed PC12 Cells Targeting Neurodegeneration |
| - | in-vitro, | AD, | PC12 |
| - | in-vivo, | AD, | NA |
| 4106- | MF, | Cognitive Decline: Current Intervention Strategies and Integrative Therapeutic Approaches for Alzheimer's Disease |
| - | Review, | AD, | NA |
| 4118- | MF, | Effects of transcranial magnetic stimulation on neurobiological changes in Alzheimer's disease |
| - | Review, | AD, | NA |
| 4119- | MF, | Therapeutic potential and mechanisms of repetitive transcranial magnetic stimulation in Alzheimer’s disease: a literature review |
| - | Review, | AD, | NA |
| 4120- | MF, | Low-Frequency Repetitive Transcranial Magnetic Stimulation of the Right Dorsolateral Prefrontal Cortex Enhances Recognition Memory in Alzheimer's Disease |
| - | Human, | AD, | NA |
| 3746- | MF, | Low-Frequency Pulsed Electromagnetic Field Is Able to Modulate miRNAs in an Experimental Cell Model of Alzheimer's Disease |
| - | in-vitro, | AD, | NA |
| 3744- | MF, | Cognitive improvement via a modulated rhythmic pulsed magnetic field in D-galactose-induced accelerated aging mice |
| - | in-vivo, | AD, | NA |
| 3742- | MF, | The role of magnetic fields in neurodegenerative diseases |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3740- | MF, | Gamma rhythm low field magnetic stimulation alleviates neuropathologic changes and rescues memory and cognitive impairments in a mouse model of Alzheimer's disease |
| - | in-vivo, | AD, | NA |
| 3739- | MF, | Early intervention using long-term rhythmic pulsed magnetic stimulation alleviates cognitive decline in a 5xFAD mouse model of Alzheimer's disease |
| - | in-vivo, | AD, | NA |
| 3737- | MF, | The Effect of Time-Dependence of 10 Hz Electromagnetic Field on Spatial Learning and Memory in Rats |
| - | in-vivo, | AD, | NA |
| 3735- | MF, | Examining the effects of extremely low-frequency magnetic fields on cognitive functions and functional brain markers in aged mice |
| - | in-vivo, | AD, | NA |
| 3734- | MF, | Extremely low frequency electromagnetic fields promote cognitive function and hippocampal neurogenesis of rats with cerebral ischemia |
| - | in-vivo, | AD, | NA |
| 3728- | MF, | Long-term exposure to ELF-MF ameliorates cognitive deficits and attenuates tau hyperphosphorylation in 3xTg AD mice |
| - | in-vivo, | AD, | NA |
| 3727- | MF, | RKIP-Mediated NF-κB Signaling is involved in ELF-MF-mediated improvement in AD rat |
| - | in-vivo, | AD, | NA |
| 3726- | MF, | Spatial memory recovery in Alzheimer's rat model by electromagnetic field exposure |
| - | in-vivo, | AD, | NA |
| 3725- | MF, | Short-term effects of extremely low frequency electromagnetic fields exposure on Alzheimer's disease in rats |
| - | in-vivo, | AD, | NA |
| 3724- | MF, | RF, | Electromagnetic Field in Alzheimer's Disease: A Literature Review of Recent Preclinical and Clinical Studies |
| - | Review, | AD, | NA |
| 3942- | MF, | Chronic-Exposure Low-Frequency Magnetic Fields (Magnetotherapy and Magnetic Stimulation) Influence Serum Serotonin Concentrations in Patients with Low Back Pain-Clinical Observation Study |
| - | Human, | AD, | NA |
| 3475- | MF, | A Pulsed Electromagnetic Field Protects against Glutamate-Induced Excitotoxicity by Modulating the Endocannabinoid System in HT22 Cells |
| - | in-vitro, | Nor, | HT22 | - | Review, | AD, | NA |
| 3488- | MFrot, | MF, | Rotating magnetic field improves cognitive and memory impairments in APP/PS1 mice by activating autophagy and inhibiting the PI3K/AKT/mTOR signaling pathway |
| - | in-vivo, | AD, | NA |
| 3489- | MFrot, | MF, | Rotating magnetic field inhibits Aβ protein aggregation and alleviates cognitive impairment in Alzheimer's disease mice. |
| - | in-vivo, | AD, | NA |
| 3745- | MFrot, | MF, | The neurobiological foundation of effective repetitive transcranial magnetic brain stimulation in Alzheimer's disease |
| - | Review, | AD, | NA |
| 212- | MFrot, | MF, | Rotating magnetic field inhibits Aβ protein aggregation and alleviates cognitive impairment in Alzheimer’s disease mice |
| - | in-vivo, | AD, | SH-SY5Y |
| 204- | MFrot, | MF, | Rotating magnetic field improved cognitive and memory impairments in a sporadic ad model of mice by regulating microglial polarization |
| - | in-vivo, | AD, | NA |
| 3838- | Moringa, | Characterization, Large-Scale HSCCC Separation and Neuroprotective Effects of Polyphenols from Moringa oleifera Leaves |
| - | in-vitro, | AD, | PC12 | - | Review, | Stroke, | NA |
| 3837- | Moringa, | Moringa oleifera: A Tree of Life as a Promising Medicinal Plant for Neurodegenerative Diseases |
| - | Review, | AD, | NA | - | Review, | Stroke, | NA | - | Review, | Park, | NA |
| 3834- | Moringa, | Moringa Oleifera Alleviates Homocysteine-Induced Alzheimer's Disease-Like Pathology and Cognitive Impairments |
| - | in-vivo, | AD, | NA |
| 3835- | Moringa, | Moringa Oleifera Alleviates Aβ Burden and Improves Synaptic Plasticity and Cognitive Impairments in APP/PS1 Mice |
| - | in-vivo, | AD, | NA |
| 3836- | Moringa, | Effects of Moringa oleifera on working memory: an experimental study with memory-impaired Wistar rats tested in radial arm maze |
| - | in-vivo, | AD, | NA |
| 3840- | Moringa, | Moringa oleifera Mitigates Memory Impairment and Neurodegeneration in Animal Model of Age-Related Dementia |
| - | in-vivo, | AD, | NA |
| 3842- | Moringa, | Bioactive Components in Moringa Oleifera Leaves Protect against Chronic Disease |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| - | in-vivo, | AD, | NA |
| 3848- | MSM, | Modulatory effect of methylsulfonylmethane against BPA/γ-radiation induced neurodegenerative alterations in rats: Influence of TREM-2/DAP-12/Syk pathway |
| - | in-vitro, | AD, | NA |
| 3852- | MSM, | DMSO modulates CNS function in a preclinical Alzheimer's disease model |
| - | in-vivo, | AD, | NA |
| 3815- | mushLions, | Neurohealth Properties of Hericium erinaceus Mycelia Enriched with Erinacines |
| - | Review, | Stroke, | NA | - | Review, | Park, | NA | - | Review, | AD, | NA |
| 3814- | mushLions, | Lion's Mane (Hericium erinaceus) Exerts Anxiolytic Effects in the rTg4510 Tau Mouse Model |
| - | in-vitro, | AD, | NA |
| 3813- | mushLions, | Erinacine A-enriched Hericium erinaceus mycelium ameliorates Alzheimer's disease-related pathologies in APPswe/PS1dE9 transgenic mice |
| - | in-vitro, | AD, | NA |
| - | in-vitro, | AD, | NA |
| 2484- | mushLions, | Neurotrophic and Neuroprotective Effects of Hericium erinaceus |
| - | Review, | Stroke, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA |
| 4035- | NAD, | VitB3, | NAD+ supplementation reduces neuroinflammation and cell senescence in a transgenic mouse model of Alzheimer's disease via cGAS-STING |
| - | in-vitro, | AD, | NA |
| 4036- | NAD, | VitB3, | NAD+ supplementation normalizes key Alzheimer’s features and DNA damage responses in a new AD mouse model with introduced DNA repair deficiency |
| - | in-vivo, | AD, | NA |
| 2933- | NAD, | Nicotinamide mononucleotide (NMN) as an anti-aging health product – Promises and safety concerns |
| - | Review, | Nor, | NA | - | NA, | AD, | NA | - | NA, | Diabetic, | NA | - | NA, | Stroke, | NA | - | NA, | LiverDam, | NA | - | NA, | Park, | NA |
| 3759- | NarG, | RT, | CGA, | RosA, | Polyphenols as acetylcholinesterase inhibitors: Structural specificity and impact on human disease |
| - | Review, | AD, | NA |
| 4224- | NarG, | The Effect of Naringin on Cognitive-Behavioral Functions, CREB/BDNF Signaling, Cholinergic Activity, and Neuronal Density in the Hippocampus of an MSG-Induced Obesity Rat Model |
| - | in-vivo, | Obesity, | NA | - | NA, | AD, | NA |
| 4156- | PB, | The HDAC inhibitor, sodium butyrate, stimulates neurogenesis in the ischemic brain |
| - | in-vivo, | AD, | NA |
| 2031- | PB, | Phenylbutyrate is a multifaceted drug that exerts neuroprotective effects and reverses the Alzheimer´s disease-like phenotype of a commonly used mouse model |
| - | in-vivo, | AD, | NA |
| 2032- | PB, | Phenylbutyric acid reduces amyloid plaques and rescues cognitive behavior in AD transgenic mice |
| - | in-vivo, | AD, | NA |
| 2033- | PB, | Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model |
| - | in-vivo, | AD, | NA |
| 4218- | PBG, | The Neuroprotective Effects of Brazilian Green Propolis on Neurodegenerative Damage in Human Neuronal SH-SY5Y Cells |
| - | in-vitro, | Nor, | SH-SY5Y | - | in-vitro, | AD, | NA |
| 4219- | PBG, | Propolis Increases Brain Derived Neurotrophic Factor Expression in the Prefrontal Cortex of Rat Stress Model |
| - | in-vivo, | AD, | NA |
| 3251- | PBG, | The Antioxidant and Anti-Inflammatory Effects of Flavonoids from Propolis via Nrf2 and NF-κB Pathways |
| - | Review, | AD, | NA | - | Review, | Diabetic, | NA | - | Review, | Var, | NA | - | in-vitro, | Nor, | H9c2 |
| 4220- | PI, | Piperine ameliorated memory impairment and myelin damage in lysolecethin induced hippocampal demyelination |
| - | in-vivo, | AD, | NA | - | in-vivo, | MS, | NA |
| 3587- | PI, | Piperine: A review of its biological effects |
| - | Review, | Park, | NA | - | Review, | AD, | NA |
| 3595- | PI, | Black pepper and health claims: a comprehensive treatise |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 3597- | PI, | Chronic diseases, inflammation, and spices: how are they linked? |
| - | Review, | AD, | NA | - | Review, | Park, | NA | - | Review, | Var, | NA |
| 3598- | PI, | Piperine attenuates cognitive impairment in an experimental mouse model of sporadic Alzheimer's disease |
| - | in-vivo, | AD, | NA |
| 3599- | PI, | Piperine, the main alkaloid of Thai black pepper, protects against neurodegeneration and cognitive impairment in animal model of cognitive deficit like condition of Alzheimer's disease |
| - | in-vivo, | AD, | NA |
| 3600- | PI, | Intranasal piperine-loaded chitosan nanoparticles as brain-targeted therapy in Alzheimer's disease: optimization, biological efficacy, and potential toxicity |
| - | in-vivo, | AD, | NA |
| 2996- | PL, | Application of longinamide in inhibiting the activation of NLRP3 inflammasome |
| - | NA, | AD, | NA | - | NA, | Park, | NA |
| 2963- | PL, | Piperlongumine activates Sirtuin1 and improves cognitive function in a murine model of Alzheimer’s disease |
| - | in-vitro, | AD, | HEK293 |
| 4866- | ProBio, | Microbiota from Alzheimer’s patients induce deficits in cognition and hippocampal neurogenesis |
| - | in-vivo, | AD, | NA |
| 3908- | PS, | The effect of phosphatidylserine-containing omega-3 fatty acids on memory abilities in subjects with subjective memory complaints: a pilot study |
| - | Human, | AD, | NA |
| 3917- | PS, | Phosphatidylserine, inflammation, and central nervous system diseases |
| - | Review, | AD, | NA | - | Review, | Park, | NA | - | Review, | Stroke, | NA |
| 3916- | PS, | The effect of soybean-derived phosphatidylserine on cognitive performance in elderly with subjective memory complaints: a pilot study |
| - | Human, | AD, | NA |
| - | Trial, | AD, | NA |
| 3914- | PS, | Soybean-Derived Phosphatidylserine Improves Memory Function of the Elderly Japanese Subjects with Memory Complaints |
| - | Trial, | AD, | NA |
| 3907- | PS, | Long-term effects of phosphatidylserine, pyritinol, and cognitive training in Alzheimer's disease. A neuropsychological, EEG, and PET investigation |
| - | Study, | AD, | NA |
| 3913- | PS, | An open trial of plant-source derived phosphatydilserine for treatment of age-related cognitive decline |
| - | Human, | AD, | NA |
| 3912- | PS, | Cognitive decline in the elderly: a double-blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration |
| - | Study, | AD, | NA |
| - | Human, | AD, | NA |
| 3910- | PS, | Neuroprotective Effect of Bean Phosphatidylserine on TMT-Induced Memory Deficits in a Rat Model |
| - | in-vivo, | AD, | NA |
| 3909- | PS, | Double-blind study with phosphatidylserine (PS) in parkinsonian patients with senile dementia of Alzheimer's type (SDAT) |
| - | Study, | AD, | NA |
| 3906- | PS, | Effects of phosphatidylserine in Alzheimer's disease |
| - | Study, | AD, | NA |
| 1990- | PTL, | Parthenolide alleviates cognitive dysfunction and neurotoxicity via regulation of AMPK/GSK3β(Ser9)/Nrf2 signaling pathway |
| - | in-vitro, | AD, | PC12 |
| 3927- | PTS, | Effects of Pterostilbene on Cardiovascular Health and Disease |
| - | Review, | AD, | NA | - | Review, | Stroke, | NA |
| 3924- | PTS, | Effect of resveratrol and pterostilbene on aging and longevity |
| - | Review, | AD, | NA | - | Review, | Stroke, | NA |
| 3923- | PTS, | Pterostilbene Supplement Benefits: Longevity Miracle or Hoax |
| - | Review, | AD, | NA |
| 3922- | PTS, | Pterostilbene attenuates amyloid-β induced neurotoxicity with regulating PDE4A-CREB-BDNF pathway |
| - | in-vivo, | AD, | NA |
| 3920- | PTS, | Resveratrol, pterostilbene, and dementia |
| - | Review, | AD, | NA |
| 3919- | PTS, | Low-dose pterostilbene, but not resveratrol, is a potent neuromodulator in aging and Alzheimer's disease |
| - | in-vivo, | AD, | NA |
| 3918- | PTS, | Pterostilbene inhibits amyloid-β-induced neuroinflammation in a microglia cell line by inactivating the NLRP3/caspase-1 inflammasome pathway |
| - | in-vitro, | AD, | BV2 |
| 3605- | QC, | Protective effect of quercetin in primary neurons against Aβ(1–42): relevance to Alzheimer's disease |
| - | Review, | AD, | NA |
| 3607- | QC, | Mechanisms of Neuroprotection by Quercetin: Counteracting Oxidative Stress and More |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3796- | QC, | BBR, | Biomarker discovery and phytochemical interventions in Alzheimer's disease: A path to therapeutic advances |
| - | Review, | AD, | NA |
| 3601- | QC, | Overviews of Biological Importance of Quercetin: A Bioactive Flavonoid |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 3602- | QC, | The flavonoid quercetin ameliorates Alzheimer's disease pathology and protects cognitive and emotional function in aged triple transgenic Alzheimer's disease model mice |
| - | in-vivo, | AD, | NA |
| 3603- | QC, | Mechanism of quercetin therapeutic targets for Alzheimer disease and type 2 diabetes mellitus |
| - | Review, | AD, | NA | - | Review, | Diabetic, | NA |
| 3604- | QC, | Quercetin enrich diet during the early-middle not middle-late stage of alzheimer’s disease ameliorates cognitive dysfunction |
| - | in-vivo, | AD, | NA |
| 3380- | QC, | Quercetin as a JAK–STAT inhibitor: a potential role in solid tumors and neurodegenerative diseases |
| - | Review, | Var, | NA | - | Review, | Park, | NA | - | Review, | AD, | NA |
| 3351- | QC, | Quercetin Exerts Differential Neuroprotective Effects Against H2O2 and Aβ Aggregates in Hippocampal Neurons: the Role of Mitochondria |
| - | Review, | AD, | NA |
| 3347- | QC, | Recent Advances in Potential Health Benefits of Quercetin |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 3343- | QC, | Quercetin, a Flavonoid with Great Pharmacological Capacity |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Arthritis, | NA |
| 3336- | QC, | Neuroprotective Effects of Quercetin in Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 3374- | QC, | Therapeutic effects of quercetin in oral cancer therapy: a systematic review of preclinical evidence focused on oxidative damage, apoptosis and anti-metastasis |
| - | Review, | Oral, | NA | - | Review, | AD, | NA |
| 3367- | QC, | Targeting Nrf2 signaling pathway by quercetin in the prevention and treatment of neurological disorders: An overview and update on new developments |
| - | Review, | Stroke, | NA | - | Review, | AD, | NA |
| 4297- | QC, | Quercetin attenuates tau hyperphosphorylation and improves cognitive disorder via suppression of ER stress in a manner dependent on AMPK pathway |
| - | in-vitro, | AD, | SH-SY5Y |
| 4296- | QC, | A Flavonoid on the Brain: Quercetin as a Potential Therapeutic Agent in Central Nervous System Disorders |
| - | Review, | AD, | NA |
| 4289- | RES, | Resveratrol Attenuates Formaldehyde Induced Hyperphosphorylation of Tau Protein and Cytotoxicity in N2a Cells |
| - | in-vitro, | AD, | NA |
| 4288- | RES, | Trans-resveratrol Inhibits Tau Phosphorylation in the Brains of Control and Cadmium Chloride-Treated Rats by Activating PP2A and PI3K/Akt Induced-Inhibition of GSK3β |
| - | in-vivo, | AD, | NA |
| 4287- | RES, | Resveratrol targeting tau proteins, amyloid-beta aggregations, and their adverse effects: An updated review |
| - | Review, | AD, | NA |
| 4286- | RES, | Neuroprotective Properties of Resveratrol and Its Derivatives—Influence on Potential Mechanisms Leading to the Development of Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 4285- | RES, | Resveratrol Rescues Tau-Induced Cognitive Deficits and Neuropathology in a Mouse Model of Tauopathy |
| - | in-vivo, | AD, | NA |
| 4284- | RES, | Resveratrol induces dephosphorylation of Tau by interfering with the MID1-PP2A complex |
| - | in-vitro, | AD, | HEK293 | - | NA, | Stroke, | NA | - | in-vivo, | AD, | NA |
| 4153- | RES, | Effect of oral resveratrol on the BDNF gene expression in the hippocampus of the rat brain |
| - | in-vivo, | AD, | NA |
| 4154- | RES, | Resveratrol improves postnatal hippocampal neurogenesis and brain derived neurotrophic factor in prenatally stressed rats |
| - | in-vivo, | AD, | NA |
| 3612- | RES, | Resveratrol in Alzheimer's disease: a review of pathophysiology and therapeutic potential |
| - | Review, | AD, | NA |
| 3613- | RES, | Resveratrol for Alzheimer's disease |
| - | Review, | AD, | NA |
| 3614- | RES, | Resveratrol--a boon for treating Alzheimer's disease? |
| - | Review, | AD, | NA |
| 3858- | RES, | Alpha-Secretase ADAM10 Regulation: Insights into Alzheimer’s Disease Treatment |
| - | Review, | AD, | NA |
| 3863- | RES, | MEL, | VitA,RetA, | Target Enzymes Considered for the Treatment of Alzheimer's Disease and Parkinson's Disease |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 2687- | RES, | Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs |
| - | Review, | NA, | NA | - | Review, | AD, | NA |
| 3099- | RES, | Resveratrol and cognitive decline: a clinician perspective |
| - | Review, | Nor, | NA | - | NA, | AD, | NA |
| 3100- | RES, | Neuroprotective effects of resveratrol in Alzheimer disease pathology |
| - | Review, | AD, | NA |
| 3057- | RES, | The therapeutic effect of resveratrol: Focusing on the Nrf2 signaling pathway |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Stroke, | NA |
| 3729- | RF, | Review of the Evidence that Transcranial Electromagnetic Treatment will be a Safe and Effective Therapeutic Against Alzheimer's Disease |
| - | in-vivo, | AD, | NA |
| 3730- | RF, | Transcranial electromagnetic treatment against Alzheimer's disease: why it has the potential to trump Alzheimer's disease drug development |
| - | Review, | AD, | NA |
| 3731- | RF, | Electromagnetic field treatment protects against and reverses cognitive impairment in Alzheimer's disease mice |
| - | in-vivo, | AD, | NA |
| 3732- | RF, | Electromagnetic treatment to old Alzheimer's mice reverses β-amyloid deposition, modifies cerebral blood flow, and provides selected cognitive benefit |
| - | in-vivo, | AD, | NA |
| - | in-vivo, | AD, | NA |
| 3736- | RF, | Long-term electromagnetic pulse exposure induces Abeta deposition and cognitive dysfunction through oxidative stress and overexpression of APP and BACE1 |
| - | in-vivo, | AD, | NA |
| 3738- | RF, | Electromagnetic Field Stimulation Therapy for Alzheimer's Disease |
| - | Review, | AD, | NA |
| 3743- | RF, | Repeated electromagnetic field stimulation lowers amyloid-β peptide levels in primary human mixed brain tissue cultures |
| - | in-vitro, | AD, | NA |
| 3461- | RF, | Electromagnetic Field Stimulation Therapy for Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 3490- | RF, | Multidimensional insights into the repeated electromagnetic field stimulation and biosystems interaction in aging and age-related diseases |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3616- | RosA, | Therapeutic effects of rosemary (Rosmarinus officinalis L.) and its active constituents on nervous system disorders |
| - | Review, | AD, | NA |
| 3615- | RosA, | Potential Therapeutic Use of the Rosemary Diterpene Carnosic Acid for Alzheimer's Disease, Parkinson's Disease, and Long-COVID through NRF2 Activation to Counteract the NLRP3 Inflammasome |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3617- | RosA, | Aroma, | Effect of aromatherapy on patients with Alzheimer's disease |
| - | in-vivo, | AD, | NA |
| 3618- | RosA, | Antioxidant and Antimicrobial Properties of Rosemary (Rosmarinus officinalis, L.): A Review |
| - | Review, | AD, | NA |
| 3619- | RosA, | Rosmarinic acid suppresses Alzheimer’s disease development by reducing amyloid β aggregation by increasing monoamine secretion |
| - | Review, | AD, | NA |
| 3620- | RosA, | Rosmarinus officinalis and Methylphenidate Exposure Improves Cognition and Depression and Regulates Anxiety-Like Behavior in AlCl3-Induced Mouse Model of Alzheimer's Disease |
| - | in-vivo, | AD, | NA |
| 3621- | RosA, | Short-Term Study on the Effects of Rosemary on Cognitive Function in an Elderly Population |
| - | Trial, | AD, | NA |
| 3623- | RosA, | Rosmarinic acid inhibits some metabolic enzymes including glutathione S-transferase, lactoperoxidase, acetylcholinesterase, butyrylcholinesterase and carbonic anhydrase isoenzymes |
| - | in-vitro, | AD, | NA |
| 3632- | RosA, | CA, | QC, | Evolving Role of Natural Products from Traditional Medicinal Herbs in the Treatment of Alzheimer's Disease |
| - | Review, | AD, | NA |
| 3757- | RosA, | Sage, | Cro, | NarG, | Caff | Food-derived Acetylcholinesterase Inhibitors as Potential Agents against Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 3792- | RosA, | Molecular docking and dynamics simulations revealed the potential inhibitory activity of honey-iQfood ingredients against GSK-3β and CDK5 protein targets for brain health |
| - | Analysis, | AD, | NA |
| 3755- | RosA, | CUR, | Development of Acetylcholinesterase (AChE) Inhibitor |
| - | Study, | AD, | NA |
| 1745- | RosA, | Rosmarinic acid and its derivatives: Current insights on anticancer potential and other biomedical applications |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 3003- | RosA, | Comprehensive Insights into Biological Roles of Rosmarinic Acid: Implications in Diabetes, Cancer and Neurodegenerative Diseases |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3028- | RosA, | Network pharmacology mechanism of Rosmarinus officinalis L.(Rosemary) to improve cell viability and reduces apoptosis in treating Alzheimer’s disease |
| - | in-vitro, | AD, | HT22 | - | in-vivo, | NA, | NA |
| 3937- | RT, | Rutin prevents tau pathology and neuroinflammation in a mouse model of Alzheimer’s disease |
| - | in-vivo, | AD, | NA |
| 3936- | RT, | Rutin improves spatial memory in Alzheimer's disease transgenic mice by reducing Aβ oligomer level and attenuating oxidative stress and neuroinflammation |
| - | in-vivo, | AD, | NA |
| 3935- | RT, | Sodium rutin ameliorates Alzheimer's disease-like pathology by enhancing microglial amyloid-β clearance |
| - | in-vivo, | AD, | NA |
| 3934- | RT, | Rutin: A Potential Therapeutic Agent for Alzheimer Disease |
| - | Review, | AD, | NA |
| 3933- | RT, | The Pharmacological Potential of Rutin |
| - | Review, | AD, | NA | - | Review, | Stroke, | NA | - | Review, | Arthritis, | NA |
| 3932- | RT, | Rutin as a Natural Therapy for Alzheimer's Disease: Insights into its Mechanisms of Action |
| - | Review, | AD, | NA |
| 4217- | Sage, | RosA, | Aroma, | Neuroprotective Potential of Aromatic Herbs: Rosemary, Sage, and Lavender |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3638- | Sage, | Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo-controlled trial |
| - | Trial, | AD, | NA |
| 3639- | Sage, | Pharmacological properties of Salvia officinalis and its components |
| - | Review, | AD, | NA | - | Review, | Var, | NA |
| 3640- | Sage, | Evaluation of Traditional Herb Extract Salvia officinalis in Treatment of Alzheimers Disease |
| - | in-vivo, | AD, | NA |
| 3641- | Sage, | Systematic Review of Clinical Trials Assessing Pharmacological Properties of Salvia Species on Memory, Cognitive Impairment and Alzheimer's Disease |
| - | Review, | AD, | NA |
| 3642- | Sage, | Chronic Supplementation with a Mix of Salvia officinalis and Salvia lavandulaefolia Improves Morris Water Maze Learning in Normal Adult C57Bl/6J Mice |
| - | in-vivo, | AD, | NA |
| 3644- | Sage, | Positive modulation of mood and cognitive performance following administration of acute doses of Salvia lavandulaefolia essential oil to healthy young volunteers |
| - | Human, | AD, | NA |
| 3645- | Sage, | RosA, | Acetylcholinesterase inhibitory, antioxidant and phytochemical properties of selected medicinal plants of the Lamiaceae family |
| - | Study, | AD, | NA |
| 3938- | SAMe, | S-adenosyl-L-methionine in the treatment of Alzheimer's disease |
| - | Human, | AD, | NA |
| 4115- | SAMe, | Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine. |
| - | Review, | AD, | NA |
| 4114- | SAMe, | S-Adenosylmethionine (SAMe) for Neuropsychiatric Disorders: A Clinician-Oriented Review of Research |
| - | Review, | AD, | NA |
| 3853- | SAS, | Sulfur-containing therapeutics in the treatment of Alzheimer's disease |
| - | Review, | AD, | NA |
| 4085- | Se, | Role of micronutrients in Alzheimer's disease: Review of available evidence |
| - | Review, | AD, | NA |
| 4721- | SeNPs, | A review on selenium nanoparticles and their biomedical applications |
| - | Review, | AD, | NA | - | Review, | Diabetic, | NA | - | Review, | Arthritis, | NA |
| 4608- | SeNPs, | Selenium Nanoparticles for Biomedical Applications: From Development and Characterization to Therapeutics |
| - | Review, | Var, | NA | - | NA, | AD, | NA |
| 4189- | Sesame, | Sesame oil mitigates memory impairment, oxidative stress, and neurodegeneration in a rat model of Alzheimer's disease. A pivotal role of NF-κB/p38MAPK/BDNF/PPAR-γ pathways |
| - | in-vivo, | AD, | NA |
| 4199- | SFN, | Sulforaphane and Brain Health: From Pathways of Action to Effects on Specific Disorders |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 4198- | SFN, | Sulforaphane epigenetically enhances neuronal BDNF expression and TrkB signaling pathways |
| - | vitro+vivo, | AD, | NA |
| 3663- | SFN, | Efficacy of Sulforaphane in Neurodegenerative Diseases |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3664- | SFN, | Sulforaphane Upregulates the Heat Shock Protein Co-Chaperone CHIP and Clears Amyloid-β and Tau in a Mouse Model of Alzheimer's Disease |
| - | in-vivo, | AD, | NA |
| 3662- | SFN, | Sulforaphane Inhibits the Generation of Amyloid-β Oligomer and Promotes Spatial Learning and Memory in Alzheimer's Disease (PS1V97L) Transgenic Mice |
| - | in-vivo, | AD, | NA |
| 3661- | SFN, | Beneficial Effects of Sulforaphane Treatment in Alzheimer's Disease May Be Mediated through Reduced HDAC1/3 and Increased P75NTR Expression |
| - | in-vitro, | AD, | NA |
| 3660- | SFN, | Sulforaphane - role in aging and neurodegeneration |
| - | Review, | AD, | NA |
| 3659- | SFN, | Epigenetic modification of Nrf2 by sulforaphane increases the antioxidative and anti-inflammatory capacity in a cellular model of Alzheimer's disease |
| - | in-vitro, | AD, | NA |
| 3658- | SFN, | Pre-Clinical Neuroprotective Evidences and Plausible Mechanisms of Sulforaphane in Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 3657- | SFN, | Sulforaphane exerts its anti-inflammatory effect against amyloid-β peptide via STAT-1 dephosphorylation and activation of Nrf2/HO-1 cascade in human THP-1 macrophages |
| - | NA, | AD, | THP1 |
| 3656- | SFN, | Chronic diseases, inflammation, and spices: how are they linked? |
| - | Review, | AD, | NA |
| 2168- | SFN, | Amelioration of Alzheimer's disease by neuroprotective effect of sulforaphane in animal model |
| - | in-vivo, | AD, | NA |
| 1484- | SFN, | Sulforaphane’s Multifaceted Potential: From Neuroprotection to Anticancer Action |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 3947- | Shank, | Convolvulus pluricaulis (Shankhapushpi) ameliorates human microtubule-associated protein tau (hMAPτ) induced neurotoxicity in Alzheimer's disease Drosophila model |
| - | in-vivo, | AD, | NA |
| 3948- | Shank, | Neuroprotective role of Convolvulus pluricaulis on aluminium induced neurotoxicity in rat brain |
| - | in-vivo, | AD, | NA |
| 3946- | Shank, | Phytochemical Profile, Pharmacological Attributes and Medicinal Properties of Convolvulus prostratus – A Cognitive Enhancer Herb for the Management of Neurodegenerative Etiologies |
| - | Review, | AD, | NA |
| 3945- | Shank, | Novel insights on acetylcholinesterase inhibition by Convolvuluspluricaulis, scopolamine and their combination in zebrafish |
| - | in-vivo, | AD, | NA |
| 3944- | Shank, | Role of Shankhpushpi (Convolvulus pluricaulis) in neurological disorders: An umbrella review covering evidence from ethnopharmacology to clinical studies |
| - | Review, | AD, | NA |
| 3943- | Shank, | Protective Mechanisms of Nootropic Herb Shankhpushpi (Convolvulus pluricaulis) against Dementia: Network Pharmacology and Computational Approach |
| - | Review, | AD, | NA |
| 3321- | SIL, | Silymarin (Milk thistle) |
| - | Review, | AD, | NA |
| 3320- | SIL, | Neuroprotective Potential of Silymarin against CNS Disorders: Insight into the Pathways and Molecular Mechanisms of Action |
| - | Review, | AD, | NA |
| 3319- | SIL, | Silymarin and neurodegenerative diseases: Therapeutic potential and basic molecular mechanisms |
| - | Review, | AD, | NA | - | Review, | Park, | NA | - | Review, | Stroke, | NA |
| 3318- | SIL, | Pharmaceutical prospects of Silymarin for the treatment of neurological patients: an updated insight |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3655- | SIL, | Protective effect of silymarin on oxidative stress in rat brain |
| - | in-vivo, | AD, | NA |
| 3654- | SIL, | Effect of silymarin on biochemical parameters of oxidative stress in aged and young rat brain |
| - | in-vivo, | AD, | NA |
| 3653- | SIL, | Silibinin ameliorates Aβ25-35-induced memory deficits in rats by modulating autophagy and attenuating neuroinflammation as well as oxidative stress |
| - | in-vivo, | AD, | NA |
| 3650- | SIL, | Silibinin: a novel inhibitor of Aβ aggregation |
| - | in-vitro, | AD, | SH-SY5Y |
| 4205- | SIL, | The Therapeutic Effect of Silymarin and Silibinin on Depression and Anxiety Disorders and Possible Mechanism in the Brain: A Systematic Review |
| - | Review, | AD, | NA |
| 4122- | Silicon, | Silicon-rich mineral water as a non-invasive test of the 'aluminum hypothesis' in Alzheimer's disease |
| - | Trial, | AD, | NA |
| 4123- | Silicon, | The potential influence of silica present in drinking water on Alzheimer's disease and associated disorders |
| - | Review, | AD, | NA |
| 4136- | Silicon, | Aluminum Should Now Be Considered a Primary Etiological Factor in Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 4134- | Silicon, | Garden Cress (Lepidium sativum) Seeds Ameliorated Aluminum-Induced Alzheimer Disease in Rats Through Antioxidant, Anti-Inflammatory, and Antiapoptotic Effects |
| - | in-vivo, | AD, | NA |
| 4133- | Silicon, | Relation between aluminum concentrations in drinking water and Alzheimer's disease: an 8-year follow-up study |
| - | Study, | AD, | NA |
| 4129- | Silicon, | Silica and aluminum in drinking water and cognitive impairment in the elderly |
| - | Study, | AD, | NA |
| 4125- | Silicon, | Oral silicon supplementation: an effective therapy for preventing oral aluminum absorption and retention in mammals |
| - | Review, | AD, | NA |
| 4127- | Silicon, | Interference of Parenteral Nutrition Components in Silicon-Mediated Protection Against Aluminum Bioaccumulation |
| - | in-vivo, | AD, | NA |
| 4891- | Sper, | Spermidine as a promising anticancer agent: Recent advances and newer insights on its molecular mechanisms |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 4895- | Sper, | Spermidine as a target for cancer therapy |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 4498- | SSE, | Selenium in Human Health and Gut Microflora: Bioavailability of Selenocompounds and Relationship With Diseases |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | IBD, | NA |
| 4151- | Taur, | Gins, | Taurine and Ginsenoside Rf Induce BDNF Expression in SH-SY5Y Cells: A Potential Role of BDNF in Corticosterone-Triggered Cellular Damage |
| - | in-vitro, | AD, | NA |
| 4157- | Taur, | Antidepressant dose of taurine increases mRNA expression of GABAA receptor α2 subunit and BDNF in the hippocampus of diabetic rats |
| - | in-vivo, | AD, | NA |
| 3966- | Taur, | The Effects of Dietary Taurine-Containing Jelly Supplementation on Cognitive Function and Memory Ability of the Elderly with Subjective Cognitive Decline |
| - | Human, | AD, | NA |
| 3965- | Taur, | Taurine-Related Nutritional Knowledge Has a Positive Effect on Intake of Taurine and Cognitive Function in the Elderly |
| - | Human, | AD, | NA |
| 3964- | Taur, | Comparison of Urinary Excretion of Taurine Between Elderly with Dementia and Normal Elderly |
| - | Human, | AD, | NA |
| 3963- | Taur, | Past Taurine Intake Has a Positive Effect on Present Cognitive Function in the Elderly |
| - | Human, | AD, | NA |
| 3962- | Taur, | The Development of Taurine Supplementary Menus for the Prevention of Dementia and Their Positive Effect on the Cognitive Function in the Elderly with Dementia |
| - | Human, | AD, | NA |
| 3961- | Taur, | Effects of Dietary Taurine Supplementation on Blood and Urine Taurine Concentrations in the Elderly Women with Dementia |
| - | Human, | AD, | NA |
| 3960- | Taur, | Versatile Triad Alliance: Bile Acid, Taurine and Microbiota |
| - | Review, | AD, | NA | - | Review, | Stroke, | NA |
| 3959- | Taur, | Taurine Directly Binds to Oligomeric Amyloid-β and Recovers Cognitive Deficits in Alzheimer Model Mice |
| - | in-vivo, | AD, | NA |
| 3958- | Taur, | Evaluation of the neuroprotective effect of taurine in Alzheimer’s disease using functional molecular imaging |
| - | in-vivo, | AD, | NA |
| - | in-vivo, | AD, | NA |
| 3950- | Taur, | Taurine Supplementation as a Neuroprotective Strategy upon Brain Dysfunction in Metabolic Syndrome and Diabetes |
| - | Review, | Diabetic, | NA | - | Review, | Stroke, | NA | - | Review, | AD, | NA |
| 3952- | Taur, | Taurine and Astrocytes: A Homeostatic and Neuroprotective Relationship |
| - | Review, | AD, | NA | - | Review, | Stroke, | NA |
| 3953- | Taur, | Role of taurine in regulation of intracellular calcium level and neuroprotective function in cultured neurons |
| - | in-vitro, | AD, | NA |
| 3956- | Taur, | Mechanisms underlying taurine protection against glutamate-induced neurotoxicity |
| - | Review, | AD, | NA |
| 3954- | Taur, | Mode of action of taurine as a neuroprotector |
| - | in-vitro, | AD, | NA |
| 2092- | TQ, | Dissecting the Potential Roles of Nigella sativa and Its Constituent Thymoquinone on the Prevention and on the Progression of Alzheimer's Disease |
| - | Review, | AD, | NA |
| 4172- | TQ, | Chronic Administration of Thymoquinone Enhances Adult Hippocampal Neurogenesis and Improves Memory in Rats Via Regulating the BDNF Signaling Pathway |
| - | in-vivo, | AD, | NA |
| 3408- | TQ, | Thymoquinone: A small molecule from nature with high therapeutic potential |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3406- | TQ, | SeNPs, | A study to determine the effect of nano-selenium and thymoquinone on the Nrf2 gene expression in Alzheimer’s disease |
| - | in-vivo, | AD, | NA |
| 3404- | TQ, | The Neuroprotective Effects of Thymoquinone: A Review |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA | - | Review, | Stroke, | NA |
| 3432- | TQ, | Thymoquinone: Review of Its Potential in the Treatment of Neurological Diseases |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3562- | TQ, | ACETYLCHOLINESTERASE AND GROWTH INHIBITORY EFFECTS–VARIOUS GRADES OF N. SATIVA OILS |
| - | Review, | AD, | NA | - | Review, | Var, | NA |
| 3554- | TQ, | Neuroprotective efficacy of thymoquinone against amyloid beta-induced neurotoxicity in human induced pluripotent stem cell-derived cholinergic neurons |
| - | in-vitro, | AD, | NA |
| 3555- | TQ, | Thymoquinone administration ameliorates Alzheimer's disease-like phenotype by promoting cell survival in the hippocampus of amyloid beta1-42 infused rat model |
| - | in-vivo, | AD, | NA |
| 3556- | TQ, | Thymoquinone alleviates the experimentally induced Alzheimer’s disease inflammation by modulation of TLRs signaling |
| - | in-vivo, | AD, | NA |
| 3557- | TQ, | Thymoquinone protects against lipopolysaccharides-induced neurodegeneration and Alzheimer-like model in mice. |
| - | in-vivo, | AD, | NA |
| - | in-vivo, | AD, | NA |
| 3559- | TQ, | Molecular signaling pathway targeted therapeutic potential of thymoquinone in Alzheimer’s disease |
| - | Review, | AD, | NA | - | Review, | Var, | NA |
| 3560- | TQ, | Protective effects of thymoquinone on D-galactose and aluminum chloride induced neurotoxicity in rats: biochemical, histological and behavioral changes |
| - | in-vivo, | AD, | NA |
| 3561- | TQ, | Studi In Silico Potensi Piperine, Piperlongumine, dan Thymoquinone Sebagai Obat Alzheimer |
| - | NA, | AD, | NA |
| 3563- | TQ, | Thymoquinone (TQ) demonstrates its neuroprotective effect via an anti-inflammatory action on the Aβ(1–42)-infused rat model of Alzheimer's disease |
| - | in-vivo, | AD, | NA |
| 3564- | TQ, | The Potential Neuroprotective Effect of Thymoquinone on Scopolamine-Induced In Vivo Alzheimer's Disease-like Condition: Mechanistic Insights |
| - | in-vivo, | AD, | NA |
| 3570- | TQ, | Thymoquinone alleviates the experimentally induced Alzheimer's disease inflammation by modulation of TLRs signaling |
| - | in-vivo, | AD, | NA |
| 3789- | UA, | Ex, | Combined Ursolic Acid and Resistance/Endurance Training Improve Type 3 Diabetes Biomarkers-Related Memory Deficits in Hippocampus of Aged Male Wistar Rats |
| - | in-vivo, | AD, | NA |
| 3788- | UA, | RosA, | Ursolic acid and rosmarinic acid ameliorate alterations in hippocampal neurogenesis and social memory induced by amyloid beta in mouse model of Alzheimer’s disease |
| - | in-vivo, | AD, | NA |
| 5023- | UA, | CA, | RosA, | Therapeutic Effect of Rosemary and Its Active Constituent on Nervous System Disorders |
| - | Review, | Park, | NA | - | Review, | AD, | NA |
| 4869- | Uro, | Urolithin A in Central Nervous System Disorders: Therapeutic Applications and Challenges |
| - | Review, | AD, | NA | - | Review, | Park, | NA | - | Review, | Stroke, | NA |
| 4868- | Uro, | Urolithin A improves Alzheimer’s disease cognition and restores mitophagy and lysosomal functions |
| - | in-vivo, | AD, | NA |
| 4867- | Uro, | Urolithin A exhibits a neuroprotective effect against Alzheimer’s disease by inhibiting DYRK1A activity |
| - | in-vivo, | AD, | NA | - | in-vitro, | AD, | HEK293 |
| 4865- | Uro, | Urolithin A suppresses high glucose-induced neuronal amyloidogenesis by modulating TGM2-dependent ER-mitochondria contacts and calcium homeostasis |
| - | in-vitro, | Diabetic, | NA | - | in-vitro, | AD, | NA |
| 4864- | Uro, | Therapeutic Potential of Mitophagy-Inducing Microflora Metabolite, Urolithin A for Alzheimer's Disease |
| - | Review, | AD, | NA |
| 4863- | Uro, | Urolithin A reduces amyloid-beta load and improves cognitive deficits uncorrelated with plaque burden in a mouse model of Alzheimer's disease |
| - | in-vivo, | AD, | NA |
| 4862- | Uro, | Neuroprotective effect of Urolithin A via downregulating VDAC1-mediated autophagy in Alzheimer's disease |
| - | in-vivo, | AD, | NA | - | in-vitro, | Nor, | PC12 |
| 4861- | Uro, | Urolithin A improves Alzheimer's disease cognition and restores mitophagy and lysosomal functions |
| - | in-vivo, | AD, | NA |
| 4860- | Uro, | Urolithins–gut Microbial Metabolites with Potential Health Benefits |
| - | Review, | Nor, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA |
| 4870- | Uro, | Urolithin A attenuates memory impairment and neuroinflammation in APP/PS1 mice |
| - | in-vivo, | AD, | NA |
| 4871- | Uro, | DHA, | LT, | A Synergistic Combination of DHA, Luteolin, and Urolithin A Against Alzheimer’s Disease |
| - | in-vitro, | AD, | NA |
| 4872- | Uro, | Urolithin A exhibits a neuroprotective effect against Alzheimer's disease by inhibiting DYRK1A activity |
| - | in-vitro, | AD, | HEK293 |
| 4873- | Uro, | Urolithin A Inhibits Anterior Basolateral Amygdala to Ventral Hippocampal CA1 Circuit to Ameliorate Amyloid-β-Impaired Social Ability |
| - | in-vivo, | AD, | NA |
| 4874- | Uro, | EGCG, | A Combination Therapy of Urolithin A+EGCG Has Stronger Protective Effects than Single Drug Urolithin A in a Humanized Amyloid Beta Knockin Mice for Late-Onset Alzheimer's Disease |
| - | in-vivo, | AD, | NA |
| 4875- | Uro, | Impact of the Natural Compound Urolithin A on Health, Disease, and Aging |
| - | Review, | AD, | NA | - | Review, | Stroke, | NA | - | Review, | ostP, | NA | - | Review, | IBD, | NA |
| 4876- | Uro, | Urolithin A in Health and Diseases: Prospects for Parkinson’s Disease Management |
| - | Review, | Park, | NA | - | Review, | AD, | NA |
| 4877- | Uro, | Urolithin-A Derivative UAS03 Improves Cognitive Deficits and Memory by Activating Nrf2 Pathways to Alleviate Oxidative Stress and Neuroinflammation |
| - | in-vivo, | AD, | NA |
| 4878- | Uro, | Activation of the Gut–Brain Interaction by Urolithin A and Its Molecular Basis |
| - | Review, | AD, | NA |
| 4879- | Uro, | Neuroprotective Effect of Urolithin A against Cerebellum Changes in Streptozotocin-Induced Alzheimer’s Disease Rat Model |
| - | in-vitro, | AD, | NA |
| 4880- | Uro, | Urolithins: A Prospective Alternative against Brain Aging |
| - | Review, | AD, | NA |
| 4884- | Uro, | A review of pomegranate supplementation: A promising remedial avenue for Alzheimer's disease |
| - | Review, | AD, | NA |
| 4833- | Uro, | Unveiling the potential of Urolithin A in Cancer Therapy: Mechanistic Insights to Future Perspectives of Nanomedicine |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | IBD, | NA |
| 4313- | VitA,RetA, | Unraveling the molecular mechanisms of vitamin deficiency in Alzheimer's disease pathophysiology |
| - | Review, | AD, | NA |
| 4312- | VitB1/Thiamine, | Pharmacological thiamine levels as a therapeutic approach in Alzheimer's disease |
| - | Review, | AD, | NA |
| 4314- | VitB1/Thiamine, | Unraveling the molecular mechanisms of vitamin deficiency in Alzheimer's disease pathophysiology |
| - | Review, | AD, | NA |
| 4310- | VitB1/Thiamine, | Pharmacological thiamine (Vitamin B1) as a treatment for alzheimer’s disease |
| - | Review, | AD, | NA |
| 4311- | VitB1/Thiamine, | Benfotiamine treatment activates the Nrf2/ARE pathway and is neuroprotective in a transgenic mouse model of tauopathy |
| - | in-vivo, | AD, | NA |
| 4327- | VitB1/Thiamine, | Plasma thiamine deficiency associated with Alzheimer's disease but not Parkinson's disease |
| - | Study, | AD, | NA |
| 4049- | VitB1/Thiamine, | Vitamin B1 (thiamine) and dementia |
| - | Review, | AD, | NA |
| 4318- | VitB12, | Unraveling the molecular mechanisms of vitamin deficiency in Alzheimer's disease pathophysiology |
| - | Review, | AD, | NA |
| 4050- | VitB12, | VitD3, | VitE, | Nutrient intake, nutritional status, and cognitive function with aging |
| - | Review, | AD, | NA |
| 4037- | VitB12, | FA, | Mechanistic Link between Vitamin B12 and Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 4058- | VitB12, | VitB6, | FA, | The preventive efficacy of vitamin B supplements on the cognitive decline of elderly adults: a systematic review and meta-analysis |
| - | Review, | AD, | NA |
| 4056- | VitB12, | VitB6, | FA, | Vitamin B12, B6, or Folate and Cognitive Function in Community-Dwelling Older Adults: A Systematic Review and Meta-Analysis |
| - | Review, | AD, | NA |
| 4054- | VitB12, | VitB6, | FA, | Role of B vitamins in modulating homocysteine and metabolic pathways linked to brain atrophy: Metabolomics insights from the VITACOG trial |
| - | Study, | AD, | NA |
| 4053- | VitB12, | VitB6, | FA, | Vitamins in Alzheimer’s Disease—Review of the Latest Reports |
| - | Review, | AD, | NA |
| 4038- | VitB12, | Vitamin B12 and Age-Related Cognitive Decline—Dementia and “Alzheimer’s Disease” |
| - | Review, | AD, | NA |
| 4048- | VitB12, | Plasma Homocysteine and Serum Folate and Vitamin B12 Levels in Mild Cognitive Impairment and Alzheimer’s Disease: A Case-Control Study |
| - | Study, | AD, | NA |
| 4047- | VitB12, | Cognitive impairment and vitamin B12: a review |
| - | Review, | AD, | NA |
| 4046- | VitB12, | Plasma Vitamin B-12 Levels and Risk of Alzheimer’s Disease: A Case-Control Study |
| - | Study, | AD, | NA |
| 4045- | VitB12, | FA, | Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial |
| - | Trial, | AD, | NA |
| 4043- | VitB12, | FA, | Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment |
| - | Trial, | AD, | NA |
| 4042- | VitB12, | Genetic determinants of low vitamin B12 levels in Alzheimer's disease risk |
| - | Review, | AD, | NA |
| 4041- | VitB12, | Thoughts on B-vitamins and dementia |
| - | Review, | AD, | NA |
| 4040- | VitB12, | FA, | Role of vitamin B12 and folic acid in treatment of Alzheimer’s disease: a meta-analysis of randomized control trials |
| - | Review, | AD, | NA |
| 4066- | VitB12, | VitB6, | FA, | Vitamin B6, B12, and Folate’s Influence on Neural Networks in the UK Biobank Cohort |
| - | Study, | AD, | NA |
| 4067- | VitB12, | VitB6, | VitD3, | Plants, Plants, and More Plants: Plant-Derived Nutrients and Their Protective Roles in Cognitive Function, Alzheimer's Disease, and Other Dementias |
| - | Review, | AD, | NA |
| 4316- | VitB3, | Unraveling the molecular mechanisms of vitamin deficiency in Alzheimer's disease pathophysiology |
| - | Review, | AD, | NA |
| - | in-vivo, | AD, | NA |
| 4033- | VitB3, | Can nicotinamide riboside protect against cognitive impairment? |
| - | in-vivo, | AD, | NA |
| 4032- | VitB3, | Modulation of cGAS-STING Pathway by Nicotinamide Riboside in Alzheimer's Disease |
| - | in-vivo, | AD, | NA |
| 4324- | VitB5, | Substantively Lowered Levels of Pantothenic Acid (Vitamin B5) in Several Regions of the Human Brain in Parkinson’s Disease Dementia |
| - | Study, | AD, | NA | - | Study, | Park, | NA |
| 4317- | VitB5, | Unraveling the molecular mechanisms of vitamin deficiency in Alzheimer's disease pathophysiology |
| - | Review, | AD, | NA |
| 4334- | VitB5, | Pantethine treatment is effective in recovering the disease phenotype induced by ketogenic diet in a pantothenate kinase-associated neurodegeneration mouse model |
| - | in-vivo, | AD, | NA |
| 4330- | VitB5, | Metabolic changes and inflammation in cultured astrocytes from the 5xFAD mouse model of Alzheimer’s disease: Alleviation by pantethine |
| - | in-vivo, | AD, | NA |
| 4329- | VitB5, | Long-Term Pantethine Treatment Counteracts Pathologic Gene Dysregulation and Decreases Alzheimer's Disease Pathogenesis in a Transgenic Mouse Model |
| - | in-vivo, | AD, | NA |
| 4328- | VitB5, | Pantethine |
| - | Review, | AD, | NA |
| 4325- | VitB5, | Localized Pantothenic Acid (Vitamin B5) Reductions Present Throughout the Dementia with Lewy Bodies Brain |
| - | Study, | AD, | NA | - | Study, | Park, | NA |
| 4323- | VitB5, | Cerebral deficiency of vitamin B5 (d-pantothenic acid; pantothenate) as a potentially-reversible cause of neurodegeneration and dementia in sporadic Alzheimer's disease |
| - | Study, | AD, | NA |
| 4052- | VitB6, | B-Vitamin Intake and Biomarker Status in Relation to Cognitive Decline in Healthy Older Adults in a 4-Year Follow-Up Study |
| - | Study, | AD, | NA |
| 4055- | VitB6, | VitD3, | Vitamin B6 and vitamin D deficiency co-occurrence in geriatric memory patients |
| - | Study, | AD, | NA |
| 4057- | VitB6, | VitB12, | FA, | Folate, Vitamin B6 and Vitamin B12 Intake and Mild Cognitive Impairment and Probable Dementia in the Women’s Health Initiative Memory Study |
| - | Study, | AD, | NA |
| 4062- | VitB6, | FA, | VitB12, | Vitamin B6, B9, and B12 Intakes and Cognitive Performance in Elders: National Health and Nutrition Examination Survey, 2011–2014 |
| - | Study, | AD, | NA |
| 4065- | VitB6, | VitB12, | FA, | Vitamin B6, B12, and Folic Acid Supplementation and Cognitive Function |
| - | Review, | AD, | NA |
| 4077- | VitB6, | FA, | VitB12, | VitD3, | VitE | Vitamin Supplementation as an Adjuvant Treatment for Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 3153- | VitC, | Vitamin C Status and Cognitive Function: A Systematic Review |
| - | Review, | AD, | NA |
| 4319- | VitC, | Unraveling the molecular mechanisms of vitamin deficiency in Alzheimer's disease pathophysiology |
| - | Review, | AD, | NA |
| 4350- | VitD3, | Vitamin D: Evidence-Based Health Benefits and Recommendations for Population Guidelines |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 4320- | VitD3, | Unraveling the molecular mechanisms of vitamin deficiency in Alzheimer's disease pathophysiology |
| - | Review, | AD, | NA |
| 4086- | VitD3, | The beneficial role of vitamin D in Alzheimer's disease |
| - | Review, | AD, | NA |
| 4182- | VitD3, | The association between vitamin D and BDNF on cognition in older adults in Southern Brazil |
| - | Study, | AD, | NA |
| 3921- | VitD3, | RES, | Vitamin D Combined with Resveratrol Prevents Cognitive Decline in SAMP8 Mice |
| - | in-vivo, | AD, | NA |
| 4088- | VitE, | Vitamin E and Alzheimer’s Disease—Is It Time for Personalized Medicine? |
| - | Review, | AD, | NA |
| 4079- | VitE, | VitC, | Effects of fruits and vegetables on levels of vitamins E and C in the brain and their association with cognitive performance |
| - | Review, | AD, | NA |
| 4087- | VitE, | Vitamin E and Alzheimer's disease: what do we know so far? |
| - | Review, | AD, | NA |
| 4089- | VitE, | Cognitive function in elderly people is influenced by vitamin E status |
| - | Study, | AD, | NA |
| 4321- | VitE, | Unraveling the molecular mechanisms of vitamin deficiency in Alzheimer's disease pathophysiology |
| - | Review, | AD, | NA |
| 4322- | VitK2, | Unraveling the molecular mechanisms of vitamin deficiency in Alzheimer's disease pathophysiology |
| - | Review, | AD, | NA |
| 4090- | VitK2, | ProBio, | Vitamin K2 Holds Promise for Alzheimer's Prevention and Treatment |
| - | Review, | AD, | NA |
| 4091- | VitK2, | The possible role of vitamin K deficiency in the pathogenesis of Alzheimer's disease and in augmenting brain damage associated with cardiovascular disease |
| - | Review, | AD, | NA |
| 2277- | VitK2, | Vitamin K2 suppresses rotenone-induced microglial activation in vitro |
| - | in-vitro, | Nor, | BV2 | - | NA, | AD, | NA | - | NA, | Park, | NA |
| 4084- | Z, | Role of micronutrients in Alzheimer's disease: Review of available evidence |
| - | Review, | AD, | NA |
| 4165- | Z, | Antidepressant-like activity of zinc: further behavioral and molecular evidence |
| - | in-vivo, | AD, | NA |
| 4164- | Z, | Zinc treatment induces cortical brain-derived neurotrophic factor gene expression |
| - | Review, | AD, | NA |
| 4191- | Zeax, | Lut, | Effects of macular xanthophyll supplementation on brain-derived neurotrophic factor, pro-inflammatory cytokines, and cognitive performance |
| - | Trial, | AD, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:38 Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid